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Liver X receptors (LXRs) are nuclear receptors that function as cellular cholesterol sensors 
and regulate cholesterol homeostasis. In addition, they have emerged as anti-inflammatory 
mediators in a broad range of inflammatory diseases. Given the high prevalence of high 
cholesterol and asthma in the developed world, we investigated the role of LXR in a mouse 
model of eosinophilic asthma. Mice deficient for both LXR isoforms, LXRα and LXRβ, 
displayed reduced clinical features of asthma, namely reduced airway inflammation, airway 
reactivity and mucus production. We showed that the attenuated airway inflammation was 
associated with a reduced expression of type 2 cytokines in cells of haematopoietic origin. 
This implies a role for LXR as a positive regulator of eosinophilic asthma through type 2 
cytokine expression. In a broader sense, we speculate that LXR signalling may underlie the 
positive association that has been described between elevated cholesterol levels in the blood 
and asthma in several epidemiological studies. High cholesterol represents a condition that 
highly activates LXR due to increased availability of endogenous LXR ligands. This implies 
that while LXR activation promotes removal of excess cholesterol through reverse cholesterol 
transport, it might also promote the development of allergic asthma due to increased 
expression of type 2 cytokines.  
Mycolic acids are highly hydrophobic lipids present in the outer membrane of Mycobacterium 
tuberculosis. We showed that, apart from their structural role, mycolic acids are also 
important immunomodulators of the host adaptive immune response and this feature is 
strongly dependent on their structural complexity. After subcutaneous immunization with 
single synthetic mycolic acids, representing the naturally occurring structures, mice displayed 
distinct CD4+ Th1 and cytotoxic CD8+ T cell immune responses in the spleen. In addition, 
pulmonary vaccination, which represents the natural route of M. tuberculosis infection, 
resulted mainly in a local Th17 response. The strength of the elicited immune response 
differed depending on the molecular structure of the mycolic acid and ranged from no 
immune response to a strong cellular immune response. This implies that the host immune 
response can thus be modulated by the bacteria by changing its mycolic acid composition. In 
addition, we demonstrated that the adjuvant activity of the distinct mycolic acids was 
attributable to the presence and the nature of the functional groups in the meromycolate chain, 
a feature that is characteristic of pathogenic mycobacteria. Finally, the potential of distinct 
mycolic acid to induce cellular immunity after a classical prime-boost vaccination strategy 
can be exploited in the development of vaccines combating intracellular pathogens, which are 
not being targeted by current vaccines. 

  
 
 
NEDERLANDSTALIGE SAMENVATTING 
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Lever X receptoren (LXRn) zijn nucleaire receptoren die als cellulaire cholesterol sensor 
fungeren en cholesterol homeostase reguleren. Daarnaast zijn het ook anti-inflammatoire 
mediatoren in verschillende chronische ontstekingsziekten. Gezien de hoge prevalentie van 
hoge cholesterol en astma in de ontwikkelde wereld, hebben we de rol van LXR in een 
muismodel van eosinofiele astma onderzocht. Muizen deficiënt voor beide LXR isovormen, 
LXRα en LXRβ, vertoonden verminderde klinische kenmerken van astma, zoals verminderde 
luchtweg inflammatie, luchtweg reactiviteit en slijmproductie. We hebben aangetoond dat de 
verminderde luchtweg inflammatie geassocieerd is met een lagere expressie van type 2 
cytokines in cellen van hematopoïetische oorsprong. Dit impliceert dat LXR fungeert als een 
positieve regulator van eosinofiele astma door type 2 cytokine expressie. In een bredere zin, 
speculeren we dat LXR signalisatie betrokken is bij de positieve associatie die is beschreven 
tussen een verhoogd cholesterolgehalte in het bloed en astma in verschillende 
epidemiologische studies. Hoge cholesterol is een aandoening die LXR activeert als gevolg 
van verhoogde beschikbaarheid van endogene LXR liganden. Dit betekent dat terwijl LXR 
activatie het verwijderen van overtollig cholesterol bevordert, het tevens kan bijdragen tot de 
ontwikkeling van allergische astma door verhoogde expressie van type 2 cytokines. 
Mycolzuren zijn zeer hydrofobe lipiden aanwezig in het buitenste membraan van 
Mycobacterium tuberculosis. In deze studie toonden we aan dat, naast een structurele rol, 
mycolzuren tevens belangrijke immunomodulatoren zijn van de gastheer adaptieve 
immuunrespons en dat deze functie sterk afhankelijk is van hun structurele complexiteit. Na 
subcutane immunisatie met specifieke synthetische mycolzuren, vertoonden muizen een CD4+ 
Th1 en cytotoxische CD8+ T cel immuunresponse in de milt. Na pulmonaire vaccinatie, welke 
de natuurlijke route van M. tuberculosis infectie is, werd vooral een lokale Th17 
immuunrespons waargenomen. De sterkte van de opgewekte immuunrespons is afhankelijk 
van de moleculaire structuur van de mycolzuur en varieerde van geen immuunrespons tot een 
sterke cellulaire immuunreactie. Dit betekent dat de immuunrespons van de gastheer kan 
worden gemoduleerd door de bacterie door zijn mycolzuur samenstelling te veranderen. 
Bovendien hebben we aangetoond dat de adjuvans activiteit van de afzonderlijke mycolzuren 
te wijten was aan de aanwezigheid en de aard van de functionele groepen in de meromycolaat 
keten, een eigenschap die kenmerkend is voor pathogene mycobacteriën. Tenslotte, vormt de 
capaciteit van bepaalde mycolzuur om cellulaire immuniteit te induceren na klassieke prime-
boost vaccinatie een interessante strategie in de ontwikkeling van vaccins voor de bestrijding 
van intracellulaire pathogenen. 
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1. Liver X receptor biology 
 
1.1 Liver X receptors are cholesterol-sensing nuclear receptors  
 
Liver X receptors (LXRs) are members of the nuclear receptor family of transcription factors 
that function to positively or negatively regulate gene expression in a ligand-dependent 
manner. Two LXR isoforms have been identified, LXRα (NR1H3) and LXRβ (NR1H2), 
which are encoded by separate genes (Fig. 1). The human LXRα gene is located on 
chromosome 11p11.2 and the LXRβ gene is located on chromosome 19q13.13. In the mouse 
genome, the LXRα gene is located on chromosome 2qE1 and the LXRβ gene is located on 
chromosome 7qB3. While the α-isoform is mainly expressed in metabolically active tissues 
such as the liver, adipose tissue, intestine and macrophages, the β-isoform is expressed 
ubiquitously at a moderate level1–6.  
 
 
Figure 1 | Gene and protein structure of mouse LXR isoforms. The mouse LXRα (NR1H3) and 
LXRβ (NR1H2) genes span about 11kb and 5kb of DNA respectively and both consist of ten exons. 
The location of translational start and stop codons is indicated and the contribution of each exon to the 
respective mRNA is shown. The mRNA gives rise to a protein structure containing a ligand-
independent transcriptional activation domain (AF1); a DNA-binding domain (DBD); a hinge region; 
a ligand-binding domain (LBD) which contains a ligand-dependent activation domain (AF2). Adapted 
from7. 
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The two LXR isoforms share substantial sequence identity and possess a domain structure that 
is common to most nuclear receptors8. The LXR protein structures contain a NH2-terminal 
region that harbours a ligand-independent transcriptional activation domain (AF1); a core 
DNA-binding domain (DBD) with two zinc finger motifs that target the receptor to specific 
DNA sequences; a hinge region that permits protein flexibility; and a large COOH-terminal 
region that encompasses the ligand-binding domain (LBD), a dimerization interface and a 
ligand-dependent activation domain (AF2) (Fig. 1). The LBD is highly conserved in structure 
between the various nuclear receptors and comprises an α helical fold that forms a 
hydrophobic ligand-binding pocket (LBP). The LBD of the LXRs encompasses 12 α helices 
(H1 – H12) and one antiparallel β turn. Binding of a ligand results in a conformational change 
of the AF2 which resides in H12. Agonist binding allows H12 to cover the ligand binding 
cavity, thereby providing one of the binding sites for co-activator complexes. The LBDs of 
the two LXR isoforms have very similar primary sequences, which has made it difficult to 
identify small molecules that bind to one LXR isoform but not the other2,9.  
Analysis of the crystal structure of LXRβ also revealed a remarkable capacity of the LBP to 
accommodate a broad range of structurally different ligands. Both LXR isoforms act as 
cholesterol sensors and are activated by oxidized cholesterol derivatives as well as by 
intermediates of the cholesterol biosynthesis pathway, such as desmosterol5,10. The oxidized 
cholesterol derivatives or oxysterols include 24(S)-hydroxycholesterol, present in the brain 
and plasma, 22(R)-hydroxycholesterol, a metabolite of steroid hormone synthesis present in 
steroid-producing organs, 24(S),25-epoxycholesterol in the liver, and 27-hydroxycholesterol 
in macrophages and plasma2,11. Binding of these ligands in the LBP leads to conformational 
changes in the receptor and mediate its transcriptional activity. Synthetic LXR agonists 
include T0901317 and GW3965 (Fig. 2). 
The cholesterol-sensing LXRs are crucial regulators of lipid and cholesterol homeostasis. 
Activated LXRs promote the elimination of excess cholesterol through expression of genes 
involved in reverse cholesterol transport. In addition to controlling cholesterol homeostasis, 
activated LXRs also exert anti-inflammatory properties, for instance through transrepression 
of TLR4-induced inflammatory signalling in macrophages12,13.  
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Figure 2 | Endogenous and synthetic LXR activating ligands. Endogenous activating ligands for 
LXR are oxidized cholesterol derivatives and intermediates of the cholesterol biosynthesis pathway, 
such as desmosterol. Synthetic LXR agonists include T0901317 and GW3965. 
 
The importance of LXRs in cholesterol homeostasis is highlighted by the association 
documented between single nucleotide polymorphisms (SNPs) in the LXR genes and 
metabolic indicators and diseases, including high density lipoprotein-cholesterol 
concentration, type 2 diabetes, obesity, coronary heart disease and metabolic syndrome14–20. 
Apart from these lipid metabolism disorders, also inflammatory and infectious diseases have 
been correlated with LXR gene polymorphisms. For instance, an increased risk for 
inflammatory bowel disease  has been linked to a SNP in the LXRβ gene21 and SNPs in both 
LXRα and LXRβ have been associated with an increased risk for Alzheimer’s disease22,23 and 
tuberculosis susceptibility24. 
 
1.2 Transcriptional regulation of gene expression by liver X receptors 
 
LXRs form obligate and permissive heterodimers with the retinoid X receptor (RXR). A 
cistrome analysis performed on mouse liver showed that 81 to 93% of all genome-wide LXR 
binding sites are shared with RXR, which is consistent with the notion that LXR binds to the 
DNA as an obligate heterodimer with RXR25. These heterodimers are bound to LXR-response 
 20 | P a g e  
 
elements (LXREs) in the DNA consisting of direct repeats of the core sequence 5’-AGGTCA-
3’ separated by 4 nucleotides (DR4). The crystal structure of human RXRα-LXRβ bound to a 
DR4-type RE revealed an extended X-shaped arrangement for this heterodimer with the 
DBDs and LBDs crossed. This organisation of the RXRα-LXRβ heterodimer is in contrast to 
the parallel domain arrangement described for other NRs that bind DR1-type REs such as the 
RXRα-PPARγ heterodimer26. In the absence of activating ligands, RXR-LXR heterodimers 
interact with co-repressors such as NCoR (nuclear receptor co-repressor) and SMRT 
(silencing mediator for retinoic acid receptor and thyroid hormone receptor). Upon binding of 
activating ligand they undergo a conformational change exchanging the co-repressors for co-
activators, which results in transcription of their target genes. We refer to this mode of action 
as transactivation (Fig. 3A). By positively regulating the expression of genes involved in 
cholesterol transport, RXR-LXR heterodimers play a key role in maintaining cholesterol 
homeostasis. In addition to a variety of genes involved in lipid and cholesterol metabolism, 
also genes involved in immunomodulation have been identified as targets of LXR 
transactivation. 
A combined cistrome and transcriptome analysis performed on a human macrophage cell line 
confirmed transactivation to be the mode of gene activation for several well-known LXR 
target genes including ATP-binding cassette transporter A1 (ABCA1)27. However, this study 
also showed that only 7.3% of the identified LXR binding sites contained a consensus DR4-
type RE. This is in accordance with a cistrome analysis performed on mouse liver, where only 
8% of the LXR binding sites contained a well-defined DR4-type RE25. In addition to indirect 
DNA binding, this was explained by the ability of LXR-RXR heterodimers to bind degenerate 
DR motif sequences resembling the DR consensus sequence. This indicated that binding in an 
in vivo chromatin context is significantly more promiscuous in terms of DNA sequence than 
the in vitro binding properties that have been used to define the consensus binding sequence. 
Furthermore, it is suggested that this promiscuous DNA binding involves stabilizing protein-
protein interactions with other transcription factors and the presence of an open chromatin 
structure.  
Apart from DR4-type REs, another frequently recognised DNA binding motifs in the LXR 
agonist-treated human macrophages is the DR1-type RE27. The presence of DR1-type REs at 
LXR binding sites suggests that PPARγ is involved in the regulation of a subset of LXR target 
genes. In the cistrome analysis on mouse liver, a substantial overlap was also shown between 
LXR and PPARα binding sites. The binding of either RXR-PPARα or RXR-LXR to these 
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overlapping binding sites was mutually exclusive, so it is assumed that LXR is not recruited 
to the DNA through association with PPARα or vice versa25. These studies indicate that while 
a cross-talk exists between LXR and PPAR subtypes, as is evidenced by the extensive sharing 
of binding sites, there is no evidence for direct binding between the nuclear receptors. 
It was previously shown that in addition to the conventional model of gene activation, an 
alternative model of gene activation exists whereby DNA binding of the LXR-RXR 
heterodimer is induced by ligand binding (Fig. 3B). It was shown that H3K9 methylation 
imposes a chromatin barrier at certain genomic loci, such as the ABCG1 gene, which prevents 
LXR binding to the DNA. Ligand activation of LXR triggers the recruitment of histone lysine 
demethylases (KDMs) to LXR through G protein pathway suppressor 2 (GPS2), thereby 
facilitating H3K9 demethylation and high affinity DNA binding, resulting in gene activation. 
This model is in accordance with the observation that the number of genome-wide LXR 
binding sites increases upon LXR agonist treatment, which is indicative of ligand-induced 
DNA binding25,27. 
Apart from directly binding to the DNA, LXR can also regulate gene expression through 
indirect binding to the DNA by interacting with other DNA-binding proteins. An example of 
an indirect association of LXR with the target gene rather than direct sequence-specific DNA 
binding is transrepression, a process whereby LXR negatively regulates inflammatory gene 
expression (Fig. 3C). In mouse peritoneal macrophages, LXR activation has been shown to 
exert anti-inflammatory effects by preventing the clearance of NCoR from the promoter of 
NFκB and/or AP-1 target genes upon inflammatory signalling13. The molecular mechanism 
underlying transrepression in macrophages involves the conjugation of small ubiquitin-like 
modifier (SUMO) proteins, namely SUMO2/3, to the LBD of ligand-bound LXR through an 
enzymatic cascade with histon deacetylase (HDAC) 4 as the E3 ligase13. SUMOylated LXRs 
bind to a SUMO2/SUMO3 interaction motif on coronin 2A (CORO2A) which is part of the 
corepressor complex and thereby inhibit the clearance of NCoR keeping the inflammatory 
genes in a repressed state13,28.  
Apart from macrophages, LXR-mediated transrepression has also been documented in other 
cell types including the liver and astrocytes. The proteins implicated in LXR SUMOylation in 
these cell types vary from the ones described for macrophages. In the mouse liver, LXRβ 
mediates transrepression of the acute phase response (APR) through a similar molecular 
mechanism as that seen in macrophages. In response to LXR ligand treatment, LXRβ was 
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conjugated to SUMO2/3 through the action of HDAC4 as E3 ligase and recruited to the 
promoter of APR responsive genes through interaction with GPS229. In addition, recent 
studies in mouse astrocytes stimulated with IFNγ showed LXR-mediated transrepression. The 
molecular mechanism differs from the one described in macrophages as SUMOylated LXRs 
formed a complex with STAT1 resulting in inhibited recruitment of STAT1 to the interferon-
regulatory factor 1 (IRF1) promoter. Different SUMOylation mechanisms were observed for 
either the LXRα or LXRβ isoform in response to LXR ligand activation. Whereas, SUMO2/3 
was conjugated to LXRα through HDAC4 as the E3 ligase, LXRβ was conjugated to SUMO1 
with PIAS1 acting as the E3 ligase30.  
The anti-inflammatory activity of LXR is modulated in an inflammatory signal-specific 
manner. For instance, LXR agonists efficiently inhibit TLR4-dependent gene activation, 
whereas TLR2-dependent gene activation is not repressed. This differential sensitivity of the 
TLR4 and TLR2 pathways to LXR repression is the result of distinct molecular mechanisms 
used to clear the NCoR complex by the TLR4 and TLR2 signalling pathways31.  
While the requirement of LXR-RXR heterodimerization has been well established for LXR-
mediated transactivation, thus far no reports have demonstrated RXR recruitment to LXR-
transrepressed genes and it is likely that heterodimerization is not required for LXR-mediated 
transrepression32.  
Ligand-dependent transrepression of inflammatory genes is also used by other nuclear 
receptors, including the glucocorticoid receptor (GR) and peroxisome proliferator-activated 
receptors (PPARs), and has been widely investigated as a therapeutic for inflammatory 
diseases33. However, developing anti-inflammatory drugs that target these nuclear receptors 
has proved to be challenging because of the elicited metabolic side-effects, related to the 
positive regulation of genes involved in metabolism. 
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Figure 3 | Molecular mechanism of LXR-mediated gene activation and transrepression. (A) 
LXRs bind to LXR response elements (LXRE) in the DNA as heterodimer with the retinoid X receptor 
(RXR). In the absence of activating ligands the heterodimer is associated with a co-repressor complex. 
Upon ligand binding the co-repressor complex dissociates and a co-activator complex is recruited, 
resulting in ABCA1 gene expression. (B) Ligand activation of LXR triggers the recruitment of histone 
lysine demethylases (KDMs) to LXR through G protein pathway suppressor 2 (GPS2), thereby 
facilitating H3K9 demethylation and high affinity DNA binding, resulting in ABCG1 gene activation. 
(C) Expression of pro-inflammatory genes is triggered by exchange of promoter-bound NCoR 
containing co-repressor complexes for co-activators upon presence of an inflammatory stimulus. LXR 
activation in macrophages promotes the specific conjugation of SUMO2/3 to LXR by histon 
deacetylase (HDAC) 4 and SUMOylated LXR is recruited to the corepressor complex via coronin 2A 
(CORO2A). Adapted from2. 
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2. Liver X receptors are important regulators of systemic and 
cellular cholesterol homeostasis 
 
Cholesterol is an essential component of mammalian cell membranes and is required for 
proper membrane permeability and fluidity. Aside from its structural role, cholesterol is also 
an important component in the synthesis of bile acids, vitamin D and steroid hormones. A 
proper control of systemic and cellular cholesterol levels is crucial for physiological 
homeostasis as elevated serum cholesterol levels are a risk factor for diseases such as 
atherosclerosis. Cholesterol levels are controlled at the systemic and cellular level by two 
distinct transcription factors: the sterol regulatory element-binding proteins (SREBPs) and the 
LXRs. These two transcription factors activate complementary gene expression programmes 
in response to altered cholesterol levels. While the SREBPs regulate biosynthesis and uptake 
of cholesterol34, LXRs regulate elimination of excess cholesterol. Here we will focus on the 
regulation of cholesterol homeostasis by the LXRs at the systemic and cellular level.  
 
2.1 Whole body lipid and cholesterol homeostasis  
 
Cholesterol is either absorbed from dietary sources or synthesized in vivo in both the liver and 
peripheral cells by a pathway whose rate-limiting step is regulated by hydroxymethylglutaryl 
(HMG)-CoA reductase. Depending on the intake, the synthesis rate changes, keeping the body 
cholesterol contents stable. This requires a strict regulation of both the biosynthetic and 
uptake pathways.  
Uptake of cholesterol from dietary fat by the intestine is mediated by ATP-binding cassette 
(ABC) transporters, ABCG5 and ABCG8 (Fig. 4). After absorption by the intestine, the 
dietary fat is packaged into chylomicrons, which are transported to peripheral tissues through 
the blood. In muscle and adipose tissues, the enzyme lipoprotein lipase (LPL) breaks down 
chylomicrons and fatty acids enter the tissue. The chylomicron remnants are taken up by the 
liver. The liver loads lipids and cholesterol onto apolipoprotein B (apoB) and secretes very-
low-density lipoproteins (VLDLs), which undergo lipolysis by lipoprotein lipase (LPL) to 
form low-density lipoproteins (LDLs). In the periphery, cells in need of cholesterol will 
express the LDL receptor (LDL-R) and take up the LDLs. The LDLs can also be taken up 
again by the liver through the LDL-R.  
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Efflux of cholesterol from peripheral tissues to the liver is known as reverse cholesterol 
transport and is mediated by high density lipoproteins (HDLs) (Fig. 4). Peripheral tissues, 
including macrophages, load cholesterol onto lipid-poor lipoproteins like apolipoprotein A-I 
(apoA-I) and apolipoprotein E (apoE) through the actions of the lipid transporters ABCA1 
and ABCG1. The free unesterified cholesterol in nascent HDLs is esterified to 
cholesterylester (CE) by the enzyme lecithin cholesterol acyltransferase (LCAT), creating 
mature HDLs. The cholesterol in HDLs is returned to the liver both directly, through uptake 
by the scavenger receptor BI (SR-BI), and indirectly, by transfer to LDLs and VLDLs through 
cholesteryl ester transfer protein (CETP). The lipid content of HDLs is altered by the enzymes 
hepatic lipase and endothelial lipase and by the transfer proteins CETP and phospholipid 
transfer protein (PLTP), affecting HDL catabolism. In the liver, cholesterol is oxidized into 
bile acids via a multi-step process of which the rate-limiting step is mediated by the 
cholesterol 7 alpha-hydroxylase (Cyp7) enzyme. A mixture of bile acids and cholesterol are 
excreted from the liver in the bile duct through the transporters ABCG5/ABCG8 and from the 
bile duct into the digestive tract for faecal excretion. Bile acids solubilise fats in the digestive 
tract and aid in intestinal absorption of fat molecules and fat-soluble vitamins. In this way, a 
part of the excreted cholesterol is reabsorbed into the bloodstream by the small intestine. In 
addition, a non-biliary pathway for cholesterol secretion, known as transintestinal cholesterol 
excretion (TICE), has been identified. Uptake of cholesterol by the enterocytes from the blood 
is thought to be mediated by apoB-containing lipoproteins such as the LDL but not the HDL. 
Cholesterol is then presumably effluxed in the lumen of the gut through the transporters 
ABCG5 and ABCG8 leading to faecal excretion6,35–37. 
Notably, LXRs have an important role in regulating cholesterol homeostasis by promoting the 
expression of genes encoding lipid-transport proteins of the ABC family, apolipoproteins and 
lipoprotein remodelling enzymes. An overview of all LXR target genes involved in 
cholesterol homeostasis is given in Table 1. Reduced expression of these genes in LXR 
deficient mice results in severely impaired removal of excess cholesterol from the body. Loss 
of LXRα activity resulted in accumulation of cholesterol in the liver, increased serum total 
cholesterol, increased LDL and reduced HDL in mice put on a high-cholesterol diet38,39. In 
addition to hypercholesterolemia, these mice also displayed reduced bile acid secretion38. The 
defects in systemic and hepatic cholesterol homeostasis were associated with the loss of the α-
isoform and were only seen when mice were put on a high-cholesterol diet38,39, indicating that 
LXRα is crucial for the elimination of excess cholesterol through biliary excretion. However, 
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combined deficiency of LXRα and LXRβ did result in foam cell formation due to cholesterol 
accumulation in the spleen, lung and arterial wall in ageing animals fed a normal low-
cholesterol diet40, indicating that both LXR isoforms are involved in cellular cholesterol 
homeostasis. On the other hand, LXR activation through agonist treatment of WT mice 
augments reverse cholesterol transport resulting in a reduction of whole-body cholesterol 
levels and raised HDL levels41–43. The latter has been correlated with the induction of direct 
LXR target genes.  
 
 
 
Figure 4 | Whole body and cellular lipid and cholesterol metabolism. The intestine absorbs dietary 
fat and packages it into chylomicrons, which are transported to peripheral tissues through the blood. 
The chylomicron remnants are taken up by the liver. Cholesterol is transported between the liver, 
peripheral macrophages and the intestine packaged into lipoprotein particles composed of lipids and 
carrier apolipoproteins. Lipoproteins can be transformed in circulation through the action of 
lipoprotein remodelling enzymes. Faecal excretion of cholesterol is mediated either through 
transformation to bile acids or through direct excretion in the intestine. Adapted from36. 
ABC, ATP-binding cassette transporter; apo, apolipoprotein; ARL7, ADP-ribosylation factor-like 7; 
CETP, cholesteryl ester transfer protein; Cyp7, cholesterol 7 alpha-hydroxylase; HDL, high-density 
lipoprotein; LCAT, lecithin cholesterol acyltransferase; LDL, low-density lipoprotein; LDL-R, LDL 
receptor; LPL,  lipoprotein lipase; PLTP, phospholipid transfer protein; SR-BI, scavenger receptor BI; 
VLDL, very-low-density lipoprotein  
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Aside from cholesterol metabolism, LXRs are also key regulators of hepatic lipogenesis 
(Table 1). As free cholesterol is highly toxic to cells, this cholesterol is esterified to fatty 
acids and further converted to triglycerides in the liver. Hepatic lipogenesis is regulated by 
LXR through upregulation of the transcription factors SREBP-1c which regulates the 
expression of several hepatic lipogenic enzymes including acetyl coenzyme A carboxylase 
(ACC), stearoyl coenzyme A desaturase-1 (SCD-1), and fatty acid synthase (FAS). These 
genes are also directly regulated by LXR, as is the carbohydrate response element-binding 
protein (ChREBP), which is a glucose-sensitive transcription factor that promotes the hepatic 
conversion of excess carbohydrate to lipid36. As a consequence, LXR deficiency is associated 
with reduced serum and hepatic triglycerides38. Conversely, an increase in hepatic and serum 
triglycerides is seen in WT mice treated with LXR agonist42. Accumulation of triglycerides in 
liver cells is known as hepatic steatosis or fatty liver, a condition generally known to be 
asymptomatic. However, high serum triglyceride levels do pose an important health threat as 
they increase the risk of coronary heart disease. As a consequence, the lipogenic activity of 
LXR forms the major obstacle in the development of LXR activating drugs. 
The LXR activated SREBP-1c and SCD1 pathways have recently also been shown to be the 
target of polyunsaturated fatty acids (PUFAs). It was shown that PUFAs feedback their own 
synthesis through repression of LXRα-mediated expression of SREBP-1c and SCD144. This 
inhibition of LXRα likely accounts for the inhibitory effect on lipogenesis described for 
PUFAs and thus also for the reduced risk for coronary heart disease effects associated with 
consumption of dietary PUFAs. This inhibitory effect of PUFAs on LXRα activity can be 
overcome by treatment with an LXR activating ligand, resulting in increased PUFAs in the 
liver45. 
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Table 1 | LXR target genes in lipid and cholesterol metabolism. Adapted from46. 
 Function Reference 
ABC transporters 
 ABCA1 Mediates cholesterol efflux from cells to apolipoproteins 43,47 
 ABCG1 Mediates efflux of cholesterol and phospolipids from cells to 
apolipoproteins as well as intracellular lipid transport 
48–50 
 ABCG4 Mediates cholesterol efflux from cells to high-density lipiproteins 51,52 
 ABCG5/8 Mediates cholesterol uptake/efflux in intestine as well as 
cholesterol efflux from hepatocytes to bile duct 
53 
 ARL7 Mediates transport of cholesterol to the membrane for ABCA1-
associated removal 
54 
Apolipoproteins 
 apoE Cholesterol carrier protein in reverse cholesterol efflux through 
HDL 
55 
 apoC cluster Cofactor for LPL in hydrolysis of triglyceride 56 
 apoD Present in adipose tissue. Function not well understood 57 
Lipoprotein remodeling 
 LPL Enzyme that hydrolyzes triglycerides in circulating chylomicrons 
and VLDL 
58 
 CETP Enzyme that mediates transfer of cholesterol esters from HDL to 
triglyceride-rich lipoproteins 
59 
 PLTP Enzyme that mediates transfers of phospholipids from 
triglyceride-rich lipoproteins to HDL 
41,60,61 
Lipogenesis 
 FAS Enzyme that catalyzes the formation of long-chain fatty acids 
from acetyl-CoA, malonyl-CoA and NADPH 
62 
 ACC Enzyme that catalyzes the carboxylation of acetyl-CoA to 
malonyl-CoA for the synthesis of long-chain fatty acids 
63 
 SCD-1 Enzyme that catalyzes the insertion of a double bond in fatty 
acyl-CoA substrates 
64 
 SREBP-1c Transcription factor that regulates expression of lipogenic 
enzymes 
42,65–67 
 ChREBP Glucose-sensitive transcription factor that promotes the hepatic 
conversion of excess carbohydrate to lipid 
68 
Bile acid biosynthesis 
 CYP7A1 Rate-limiting enzyme in the conversion of cholesterol to bile 
acids (only in mouse) 
69 
Lipoprotein uptake 
 SR-BI HDL receptor involved in uptake of lipoprotein particle 70,71 
 LDL-R LDL receptor involved in uptake of lipoprotein particle 72 
 IDOL E3 ubiquitin ligase that triggers ubiquitination of the LDL-R 
resulting in degradation and in lowered lipoprotein uptake 
73 
 
ABC, ATP-binding cassette transporter; ACC, acetyl CoA carboxylase; ARL7, ADP-ribosylation 
factor-like 7; APO, apolipoprotein; CETP, cholesterol ester-transfer protein; ChREBP, carbohydrate 
response element-binding protein; CYP7A1, cytochrome P450 7A1; FAS, fatty acid synthase; IDOL, 
inducible degrader of LDL receptor; LDL-R, low density lipoprotein receptor; LPL, lipoprotein lipase; 
PLTP, phospholipid transfer protein; SCD-1, steroyl CoA desaturase 1; SREBP-1c, sterol-regulatory 
element-binding protein 1c; SR-BI, scavenger receptor BI 
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2.2 Cellular cholesterol homeostasis  
 
Cellular cholesterol levels in peripheral cells such as macrophages reflect a balance between 
cholesterol uptake, efflux and endogenous synthesis. Under conditions of low cellular 
cholesterol, SREBP precursors are processed resulting in active SREBP that promotes 
expression of proteins required for cholesterol synthesis and cholesterol uptake, such as HMG 
CoA reductase and the LDL receptor. Under these conditions, LXR-RXR heterodimers are 
bound by co-repressor complexes and repress expression of genes encoding proteins 
mediating cholesterol efflux. Under conditions of cholesterol excess, oxysterols bind to LXR, 
causing the recruitment of co-activator complexes and transcription of target genes encoding 
proteins mediating cholesterol efflux. In addition to LXR activation, oxysterols also suppress 
SREBP processing.  
Cholesterol efflux is mediated by LXR through the induction of the plasma membrane 
cholesterol transporter ABCA1, which promotes the transfer of cholesterol to extracellular 
lipid-poor apolipoproteins, such as apoAI and apoE, resulting in nascent HDL (Fig. 4). In 
addition, LXR-mediated cholesterol efflux to mature HDL depends on ABCG174,75, which is 
an intracellular cholesterol transporter that localizes to endocytic vesicles and facilitate the 
redistribution of intracellular cholesterol away from the endoplasmic reticulum76. An 
additional target gene of LXR whose product cooperates with ABCA1 to accomplish 
cholesterol efflux is ADP-ribosylation factor-like 7 (ARL7), which has been shown to 
transport cholesterol to the membrane for ABCA1-associated removal and thus may be 
integral to the LXR-dependent efflux pathway54. LXR maintains cholesterol homeostasis not 
only through regulation of cholesterol efflux, but also through regulation of cholesterol 
uptake. LXR activation results in lowered LDL uptake through expression of IDOL (inducible 
degrader of LDL-R), an E3 ubiquitin ligase that triggers ubiquitination of the LDR, thereby 
targeting it for degradation73. 
A primary function of LXRs in macrophages consists of maintaining cellular cholesterol 
homeostasis through mediating efflux of excess cholesterol to HDL particles. Considering 
that atherosclerosis is characterised by the presence of foamy macrophages in the artery wall, 
LXRs are endogenous inhibitors of atherogenesis and LXR activation consequently results in 
reduced atherosclerosis symptoms in mice, which will be discussed in detail further on in this 
chapter (part 4.1).  
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2.3 Cholesterol homeostasis in the central nervous system 
 
The brain is the most cholesterol-rich organ of the body, containing about 20% of the body’s 
total cholesterol77. Cholesterol is a major constituent of myelin and the plasma membrane of 
glial cells and neurons. Apart from a structural role, cholesterol is also involved in neuronal 
development, synaptogenesis, learning and memory78. Even though cholesterol is essential for 
the structure and function of the central nervous system (CNS), high levels of cholesterol are 
related to neurodegenerative diseases. For this reason, cholesterol metabolism in the brain is 
tightly regulated77. The blood-brain barrier prevents the uptake of lipoprotein cholesterol from 
the circulation. So unlike in other organs, cholesterol in the brain is mainly synthesized de 
novo77. Cholesterol is transported between cells of CNS after loading the cholesterol on the 
carrier protein apoE in an ABCA1-dependent manner (Fig. 5). The formed lipoprotein 
particles are recognized by the LDL-receptor, which mediate lipoprotein uptake. Excess 
cholesterol is metabolized to 24(S)-hydroxycholesterol (24S-OH-C) which can cross the 
blood-brain barrier (BBB) and pass into the circulation. The rate-limiting enzyme for this 
conversion is cholesterol 24-hydroxylase, which is encoded by the gene Cyp46 and is mainly 
located in neurons. 
LXRs are important regulators of cholesterol homeostasis in the body and have also been 
implicated in cholesterol homeostasis in the CNS. Even though both LXR isoforms are 
expressed in the brain, LXRβ is expressed at the highest level79 and is also expressed during 
brain development80. LXRβ is expressed throughout the brain, whereas LXRα is selectively 
expressed in the subcortical regions but is absent from the cortex of the brain79. Both isoforms 
are expressed in glial cells (microglia, astrocytes and oligodendrocytes) as well as in 
neurons79. Accumulating evidence shows a role for LXR in the regulation of cholesterol 
metabolism in the CNS. In studies on LXRα-/-β-/- mice an increased number of lipid-loaded 
cells81 have been observed in the brain as well as a decrease in the expression of LXR target 
genes involved in cholesterol transport81,82. Moreover, treatment of mice with a synthetic 
LXR agonist results in upregulation of these genes in the brain79,81–83. Treatment of primary 
cells with this LXR agonist resulted in upregulation of LXR target genes together with 
cholesterol efflux in astrocytes79,83 and oligodendrocyte84 cultures but not in neuronal 
cultures79. The observation that LXR-mediated cholesterol efflux is observed in glial cells but 
not in neuronal cells is in agreement with an early hypothesis that neurons show a low level of 
de novo cholesterol synthesis and acquire cholesterol through uptake of apoE lipoproteins, 
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secreted from astrocytes85. Apart from a central role in cholesterol homeostasis in the central 
nervous system, LXR has also been shown to suppress STAT1 inflammatory signalling in 
IFNγ-stimulated astrocytes30. The combined anti-inflammatory properties of LXR and its role 
in cholesterol homeostasis, makes LXR a prime target for the treatment of neurodegenerative 
diseases like Alzheimer's disease and multiple sclerosis, which will be discussed in detail 
further on in this chapter (part 4.2 and 4.3).  
 
 
 
 
 
Figure 5 | Cholesterol homeostasis in the central nervous system. Cholesterol is synthesized de 
novo in glial cells such as astrocytes, and transported to neurons after ATP binding cassette (ABC) 
A1-dependent loading of the cholesterol on apolipoprotein (apo) E. Excess cholesterol is metabolized 
to 24(S)-hydroxycholesterol (24S-OH-C) and can cross the blood brain barrier to enter in the 
circulation. Lipidated apoE chaperones amyloid-β for uptake and proteolytic degradation by microglia.   
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3. Liver X receptor in immune cells  
 
3.1 Macrophages  
 
LXRs are highly expressed in macrophages and play diverse roles in their biology. In the 
beginning of this chapter (part 2.2), we discussed the role of LXR as a cellular cholesterol-
sensor that promotes the expression of genes involved in cholesterol efflux upon exposure of 
the macrophage to excess cholesterol levels. Apart from regulating macrophage cholesterol 
homeostasis, LXR activation also inhibits the expression of pro-inflammatory genes, such as 
iNOS, COX-2 and IL-6, after LPS stimulation in macrophages. This anti-inflammatory effect 
is due to LXR-mediated transrepression of TLR4-induced inflammatory signalling, which was 
discussed earlier in this chapter (part 1.2). 
A critical function of macrophages in tissue homeostasis as well as in resolution of 
inflammation is the removal of apoptotic cells by a specialized phagocytic process called 
efferocytosis86. Through clearance of apoptotic cells, macrophages ensure that cellular 
remnants are contained and eliminated without initiating an inflammatory response. After 
apoptotic cell engulfment, efferocytic macrophages produce anti-inflammatory mediators 
such as IL-10 and TGFβ to prevent an immune response to self-antigens86. Defective 
apoptotic cell clearance is associated with the development of autoimmunity and other 
chronic inflammatory disorders including atherosclerosis86,87. Macrophage engulfment of 
apoptotic cells was shown to activate LXR, likely through the accumulation of membrane-
derived cholesterol (Fig. 6). LXR in turn induced the expression of MER, a receptor tyrosine 
kinase which is involved in recognition of phosphatidylserine (PS) on dying cells, thereby 
providing a positive feedback to promote further apoptotic cell uptake. In addition, 
macrophage uptake of apoptotic cells was also shown to trigger LXR-mediated repression of 
the pro-inflammatory mediators IL1-β and MCP-1. In this way, activation of MER expression 
and repression of pro-inflammatory signalling make LXR a key regulator of apoptotic cell 
clearance88. As a consequence, mice deficient for both LXR isoforms displayed defective 
clearance of apoptotic cells, increased inflammation and developed signs of age-dependent 
auto-immune disease. Accordingly, treatment with LXR agonists had beneficial effects on the 
progression of autoimmune disease in a mouse model of lupus-like autoimmunity88. In 
addition to LXR, also nuclear receptors PPARγ and PPARδ are important mediators of 
 33 | P a g e  
 
apoptotic cell clearance through increased expression of efferocytic receptors, such as CD36, 
and reduced inflammation87. 
 
Figure 6 | LXR activation promotes apoptotic cell clearance and provides a link to neutrophil 
homeostasis. Uptake of apoptotic cells by macrophages activates LXR, which in turn induces the 
expression of MER, to further enhance apoptotic cell clearance, and represses expression of 
inflammatory mediators, inducing immune tolerance. In addition, LXR activation, upon clearance of 
apoptotoc neutrophils, was shown to repress the IL-23 / IL-17 / G-CSF axis resulting in reduced 
neutrophil efflux from the bone marrow. 
 
3.2 Neutrophil homeostasis  
 
Leukocytes represent the cell type with the highest turn-over in the body. Especially 
neutrophils have a very short half-life of 3 to 12 hours and it has been estimated that on a 
daily basis 107 to 1011 neutrophils are released into the circulation from the bone marrow in 
mice and humans, respectively. Accordingly, an equivalent number of senescent neutrophils 
are removed from circulation by resident macrophages in the liver, spleen and bone marrow in 
order to maintain neutrophil homeostasis89. Clearance of apoptotic neutrophils by 
macrophages in the spleen and liver was shown to induce LXR-mediated expression of the 
efferocytic receptor MER, further promoting apoptotic cell clearance (Fig. 6)89. In addition, 
efferocytosis-induced LXR activation was also shown to contribute to neutrophil homeostasis 
through repression of the IL-23/IL-17 signalling axis that regulates neutrophil efflux from the 
bone marrow89. Macrophage phagocytosis of apoptotic neutrophils was shown to repress the 
expression of IL-23 in an LXR-dependent manner. In the absence of phagocytosis, IL-23 
production is elevated, resulting in the secretion of IL-17 from T cells. In turn, IL-17 induces 
G-CSF production in the bone marrow that stimulates granulopoiesis and efflux from the bone 
marrow90,91. In this way, LXR mediates the coupling between peripheral clearance of 
apoptotic neutrophils and the release of new neutrophils by the bone marrow, contributing to 
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neutrophil homeostasis. In case of LXR deficiency, the repression on the IL-23/IL-17 
cytokines cascade is released and higher number of neutrophils will be released in circulation 
resulting in a modest neutrocytosis89. The clearance of apoptotic neutrophils in the bone 
marrow was recently shown to be a crucial component in the rhythmic egress of new 
neutrophils in the circulation92.  
 
3.3 Immune cell proliferation 
 
Cholesterol is an essential component of cell membranes. Dividing cells therefore require 
adequate levels of cholesterol. Cholesterol levels in dividing T cells are regulated by the 
reciprocal regulation of LXR and SREBP transcriptional pathways. Upon T cell activation, an 
increased activity in the SREBP pathway is responsible for cholesterol synthesis and uptake, 
and a decreased activity in the LXR pathway results in cholesterol accumulation, allowing for 
membrane formation and cellular proliferation. Inhibition of LXR signalling is due to the 
induction of the oxysterol-metabolizing enzyme SULT2B1, which inactivates endogenous 
LXR ligands93. As a consequence, treatment with synthetic LXR ligands abrogates the effect 
of elimination of oxysterols and results in cholesterol efflux and exerts an anti-proliferative 
effect93,94. This effect is lost in T cells lacking the ABCG1 transporter, indicating a direct link 
between the anti-proliferative activities of LXR ligands and cholesterol efflux93. The intrinsic 
effect on lymphocyte proliferation is mediated by the LXRβ isoform, which is the only LXR 
isoform expressed by T cells.  
Apart from T cells, LXR agonists also inhibit the proliferation of M-CSF stimulated 
macrophages93,95. This anti-proliferative effect was shown to be independent of functional 
expression of the cholesterol transporters ABCG1 and ABCA1. This shows that macrophage 
proliferation in response to M-CSF, in contrast to T cell proliferation, does not require 
downregulation of LXR-dependent pathways. Different mechanisms may thus account for the 
anti-proliferative effects of LXR agonists in distinct cell types. 
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3.4 Th17 differentiation  
 
Recent studies have identified LXR as a negative regulator of Th17 differentiation and Th17-
dependent auto-immune diseases such as multiple sclerosis96. The molecular mechanism by 
which LXR constrains Th17 differentiation appears to be multifactorial. As discussed above, 
LXR activation impairs T cell proliferation through mediating cholesterol efflux93. LXRs also 
indirectly influence Th17 differentiation through LXR-mediated repression of the expression 
of key Th17 differentiation cytokines, IL-6 and IL-23, by APCs12,89,97. In addition, LXR-
induced SREBP-1 inhibits IL-17 transcription by binding to the IL-17 promoter through 
interaction with the aryl hydrocarbon receptor (Ahr), a transcription factor known to enhance 
Th17 cell responses96.  
A growing body of evidence suggests a pathogenic role for Th17 cells in several autoimmune 
diseases, including multiple sclerosis. Loss of LXR activity was shown to be associated with 
more severe symptoms in a mouse model of multiple sclerosis and this correlated with highly 
increased numbers of Th17 cells in the central nervous system96. In accordance, LXR agonist 
treatment reduced the number of Th17 cells in a LXR-dependent manner resulting in an 
attenuation of the clinical symptoms96. Other Th17-mediated autoimmune diseases in which 
LXR has been reported to display a protective role include rheumatoid arthritis98,99, 
inflammatory bowel disease100 and psoriasis101,102. The involvement of LXR-mediated 
repression of Th17 differentiation has, however, not yet been investigated in these models.  
Apart from a role in autoimmune diseases, Th17 cells are crucial in the development of host 
antimicrobial immune responses against a variety of pathogens including Mycobacterium 
tuberculosis103. Strikingly, a decrease in Th17 cells was observed in the lungs of M. 
tuberculosis infected LXR deficient mice, which showed a reduced resistance to the 
bacteria104. Conversely, treatment of WT mice with LXR agonists increased the number of 
Th17 cells upon infection. Thus, while LXR activity has been shown to reduce Th17 
differentiation in autoimmune diseases like multiple sclerosis, it increases the number of Th17 
cells in a setting of infectious disease, indicating that different molecular mechanisms may 
mediate the effect of LXR on Th17 immune responses in distinct inflammatory conditions. 
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3.5 Dendritic cells 
 
Dendritic cells (DCs) are the main antigen-presenting cell responsible for initiating adaptive 
immune responses. Several studies have investigated the role of LXR in myeloid DC 
differentiation and function by means of GM-CSF differentiated monocytes (Fig. 7), i.e. 
monocyte derived DCs (MDDC) in the case of human studies or bone marrow derived DCs 
(BMDC) in the case of mouse studies.  
Expression data have revealed that LXRα is upregulated during both MDDC and BMDC 
differentiation, whereas LXRβ remains expressed at low level throughout differentiation105–
108, implying a role for LXRα, but not LXRβ, in myeloid DC differentiation. This was 
recently confirmed by a study showing that LXRα overexpression and LXR activation 
promote GM-CSF driven myeloid DC differentiation in mouse bone marrow cultures108.  
 
 
Figure 7 | LXR function in myeloid dendritic cells (DC). LXRα is upregulated during GM-CSF-
driven DC differentiation and LXR activation increases DC differentiation. Expression of chemokine 
receptor CCR7 is increased in immature DCs and decreased in mature DCs upon LXR agonist 
treatment. Studies on the effect of LXR activation on functional capacity of DCs have yielded 
contradictory results, both describing an increase and decrease in maturation marker expression, pro-
inflammatory cytokine expression and T cell proliferation. 
 
Upon sensing of a pathogen, DC maturation results in upregulation of the chemokine receptor 
CCR7, enabling the DC to migrate to the draining lymph nodes. Studies investigating the 
migratory capacity of DCs showed that LXR activation of immature human MDDCs resulted 
in upregulation of CCR7 and increased migratory capacity109. In contrast, LXR agonists 
inhibited CCR7 expression in LPS-matured human MDDCs and mouse BMDCs in an LXRα-
 37 | P a g e  
 
dependent manner, directly resulting in a decrease in migratory capacity of the mature 
DCs109–111. Second to CCR7 upregulation, DC maturation also results in increased expression 
of co-stimulatory molecules, including CD80 and CD86, and production of a distinct set of 
cytokines, specific to the encountered pathogen, driving naïve T cell proliferation and 
differentiation. Whereas numerous studies have shown that treatment with LXR agonists, 
either during DC differentiation or LPS maturation, resulted in reduced expression of the 
maturation markers CD80 and CD86, reduced secretion of pro-inflammatory cytokine such as 
IL-12, IL-6 and IL-23 and reduced T cell proliferation and differentiation89,97,106,111, others 
have shown the opposite effect107,108. The contradictory results about the role of LXR in DC 
maturation suggest that DCs are very sensitive to changes in LXR signalling and can be the 
result of different experimental protocols or of LXR ligand treatment at different DC 
maturation stages. 
 
4. Liver X receptor in inflammatory diseases 
 
4.1 Atherosclerosis 
 
Atherosclerosis is a progressive disease characterized by accumulation of lipids in the wall 
of arterial blood vessels. Early atherosclerotic lesions develop when cholesterol-rich LDLs 
accumulate in the artery wall and are subsequently oxidized resulting in oxidized LDL 
(oxLDL). Macrophages efficiently take up the oxLDL through the scavenger receptor A (SR-
A) or CD36 and become foamy macrophages due to intracellular lipid accumulation. Early 
lesions further develop into complex atherosclerotic plaques, that can cause an occlusion of 
the blood vessel and a myocardial infarction, mostly due to formation of a blood clot after 
rupture of the plaque36,87,112. 
As was discussed in the beginning of this chapter (part 2.1 and 2.2), LXRs are key regulators 
of systemic and cellular cholesterol homeostasis, making them endogenous inhibitors of 
atherogenesis (Fig. 8)12,113,114. Apart from upregulation of LXR target genes involved in the 
reverse cholesterol transport pathway, LXR also further enhances cholesterol efflux by 
inducing expression of LXRα through an autoregulatory loop, though only in human 
macrophages115–117. In accordance, treatment with synthetic LXR agonists reduced 
atherosclerosis in the two common mouse models, namely LDLR-/- and apoE-/- mice113,114. 
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Conversely, loss of LXR activity in bone marrow-derived cells increased atherosclerotic 
lesion formation in these same models118–120.  
 
 
Figure 8 | Reciprocal regulation of inflammation and lipid homeostasis by LXR and PPARγ in 
atherosclerotic foam cells. Uptake of oxidised LDL (oxLDL) by macrophages results in activation of 
the nuclear receptors LXR and PPARγ. Activation of LXR promotes lipid efflux and inhibits TLR4-
mediated inflammation. The LXRα-signalling pathway is further enhanced by a positive 
autoregulatory feedforward loop and by PPARγ through upregulation of LXRα and cholesterol 27-
hydroxylase (Cyp27). Activation of PPARγ also results in increased oxLDL uptake by upregulation of 
the scavenger receptor (SR)-A and CD36 and inhibition of inflammation. Cholesterol ester (CE) 
storage in lipid droplets results in foam cell formation. 
 
Even though uptake of oxidized LDL provides the macrophage with LXR-activating 
oxysterols, the dominant endogenous LXR ligand found to accumulate in macrophage foam 
cells is desmosterol (see Fig. 2 for structure), the final intermediate in the cholesterol 
biosynthesis pathway121. Excess cholesterol was shown to suppress the activity of 24-
dehydrocholesterol reductase (DHCR24), the enzyme responsible for the conversion of 
desmosterol to cholesterol, and in this way resulted in desmosterol accumulation in 
cholesterol-loaded macrophages121. Apart from oxysterols, oxidised fatty acids are also 
present in the oxLDL and activate the nuclear receptor PPARy of which LXRα is a direct 
target gene122. PPARγ activation leads to upregulation of cholesterol 27-hydroxylase 
(Cyp27a1), that converts cholesterol to 27-hydroxycholesterol, an endogenous ligand of 
LXR123,124. In addition to enhancing LXR-mediated cholesterol efflux by promoting LXR 
expression and production of endogenous LXR ligands, PPARγ also stimulates oxLDL uptake 
by upregulating the expression of the scavenger receptors SR-A and CD36. In coupling the 
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pathway of oxLDL uptake and LXR-mediated lipid efflux, PPARγ activation enhances the 
ability of the macrophage to remove oxLDL from the vessel wall and protects from 
atherosclerosis125,126.  
Apart from foam cell formation, atherogenesis is also characterized by macrophage 
infiltration in the artery wall. In advanced atherosclerotic lesions, macrophages are major 
contributors to the inflammatory response through secretion of pro-inflammatory mediators 
and matrix-degrading proteases36,87,112. Activation of LXR was shown to inhibit genes 
involved in the innate immune response in LPS-activated macrophages through 
transrepression, while simultaneously inducing those involved in lipid metabolism12. This 
indicates that LXR activation not only combats the development of atherosclerotic lesions by 
stimulating lipid efflux from macrophages but also by inhibiting the production of 
inflammatory mediators such as MCP-1, IL-6, IL-1β and MMP-9 in the artery wall, and 
hereby reduces the influx of new macrophages in the atherosclerotic lesion and lesion 
remodelling12,127.  
 
4.2 Alzheimer’s disease 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease of the brain and is the 
most common form of dementia. It is characterized by the accumulation and deposition of 
amyloid-β peptides within the brain. Cholesterol has been shown to play an important role in 
amyloid-β pathology in AD which is demonstrated by the fact that increased cellular 
cholesterol levels are associated with higher amyloid-β levels in the brain and increased risk 
of AD6,128. Discovery of SNPs in genes involved in cholesterol metabolism such as 
ABCA1129, ABCA2130, LXRα22, LXRβ131 and Cyp46132,133 are also associated with increased 
risk for AD. This further strengthens the role of cholesterol metabolism in AD pathology. 
Cholesterol metabolism in the brain is regulated by LXRs, as was discussed in the beginning 
of this chapter (part 2.3), and as such LXRs have also been investigated for their role in AD 
pathology. Deletion of either LXRα or LXRβ in a transgenic mouse model of AD led to a 
marked increase in amyloid-β deposition and an AD-like pathology82. Complementing these 
observations, several studies have shown that synthetic LXR agonists reduced amyloid-β load 
and have therapeutic effects in mouse models of AD134–137. The beneficial effects of LXRs on 
AD pathology are attributed to the regulation of ABCA1 and apoE expression. Apart from its 
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role in lipid transport, apoE has been shown to facilitate proteolytic degradation of amyloid-
β135. Removal of amyloid-β by proteolytic degradation can either occur through extracellular 
proteinases or after phagocytosis by microglia138. The lipidation state of apoE is an important 
determinant in proteolytic degradation of amyloid-β. Where poorly lipidated apoE shows a 
reduced capacity to chaperone amyloid-β degradation, highly lipidated apoE makes it more 
susceptible for proteolytic degradation135. Activation of LXRs by a synthetic agonist increases 
ABCA1-dependent lipid loading of apoE and thus stimulated apoE-mediated amyloid-β 
proteolytic degradation.  
In addition to lipid dysregulation, amyloid-β depositions in the brain of AD patients are also 
associated with local innate inflammatory responses mediated by microglia and astrocytes. 
Microglia normally act to clear amyloid-β aggregates by phagocytosis but this process is 
suppressed in the presence of inflammatory cytokines139. Activation of LXRs has been shown 
to inhibit microglial inflammation induced by amyloid-β as well as to restore the phagocytic 
potential of the microglia cells82,140. This shows that the reduced AD pathology seen in mice 
treated with LXR agonists can also be the result of LXR-mediated restoration of microglia 
phagocytosis and clearance of amyloid-β plaques by microglia82. The fact that LXR has a 
beneficial effect on both cholesterol metabolism and innate inflammation makes LXR ligands 
promising compounds for the treatment of AD. 
 
4.3 Multiple sclerosis 
 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous 
system (CNS) with progressive neurodegeneration141,142. The most commonly used animal 
model to study MS is experimental autoimmune encephalomyelitis (EAE). In this model, 
mice are immunized with a myelin antigen together with Complete Freund’s Adjuvant and 
pertussis toxin to induce CNS inflammation and demyelination, leading to tail and hind limb 
paralysis. LXR has been shown to play a protective role in EAE development as LXRαβ 
deficient mice developed more severe EAE than WT mice96. Complementing these data, 
treatment of WT mice with LXR agonists resulted in a suppression of clinical EAE, reduced 
CNS inflammation and reduced demyelination in a LXR-dependent manner94,96,143. While the 
etiology of MS remains poorly understood, it is most commonly accepted that MS is an 
autoimmune disease in which myelin-reactive Th17 cells enter the CNS and attack the myelin 
sheath of the neurons resulting in neuroinflammation and demyelination144,145. A way in 
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which LXR has been suggested to exert a protective role in EAE development is through 
inhibiting differentiation of these Th17 cells96. LXR-dependent inhibition of Th17 
differentiation is mediated by transcriptional regulation of SREBP-1 that in his turn 
suppresses Th17 differentiation by binding to the E-box element in the IL-17 promoter, 
physically interacting with aryl hydrocarbon receptor (Ahr) and inhibiting Ahr-controlled IL-
17 transcription96. 
An additional way in which LXR might influence MS is through regulation of cholesterol 
homeostasis in oligodendrocytes84. Oligodendrocytes are the myelin-producing glial cells of 
the CNS and cholesterol synthesis and transport have been shown to be crucial for proper 
myelination146. In accordance with experimental data, also epidemiological studies have 
shown a correlation between cholesterol dysregulation and MS147. As cholesterol homeostasis 
has been shown to be important for formation and maintenance of myelin in the CNS, the role 
of cholesterol regulator LXR was also investigated. Activation of LXR in oligodendrocytes 
was shown to induce expression of LXR target genes involved in cholesterol transport as well 
as to stimulate cholesterol efflux, indicating that LXR is a regulator of cholesterol 
homeostasis in oligodendrocytes84. Expression of LXRβ is upregulated during 
oligodendrocyte differentiation and maturation84,148. In addition, mice deficient for either 
LXRβ alone or for both isoforms have been reported to display thinner myelin sheaths of 
neural axons both in the CNS81,148 and in the periphery149. Thin myelin sheaths are indicative 
of a defect in myelin development and shows that LXR is involved in CNS myelination. This 
shows that LXRs are involved in maintaining normal myelin in the central nervous system 
(CNS) and that abnormal myelination, associated with LXR deficiency, might play a role in 
the increased susceptibility of these mice to EAE94.  
 
4.4 Arthritis 
 
Rheumatoid arthritis (RA) is a chronic auto-immune inflammatory disease characterized by 
synovial inflammation and destruction of the cartilage and the bone, leading to instability and 
deformity of the joint. The collagen-induced arthritis (CIA) model is the most commonly used 
mouse model of rheumatoid arthritis. Autoimmune arthritis is induced in this model by 
immunization with an emulsion of complete Freund's adjuvant and type II collagen150. Mice 
deficient for both LXR isoforms have been shown to develop more severe clinical arthritis 
symptoms as compared to WT mice151, implying a protective role for LXR in arthritis. 
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Nevertheless, conflicting reports exist regarding whether treatment with LXR agonists 
reduces or exacerbates arthritis symptoms. On the one hand, mice receiving the LXR ligands 
either in the feed or through daily oral gavage displayed attenuated clinical arthritis symptoms 
together with reduced inflammatory cell infiltration, reduced levels of pro-inflammatory 
cytokines and diminished bone erosion98,99. On the other hand, multiple reports by Asquith et 
al. reported that daily intraperitoneal treatment with LXR agonists resulted in an aggravation 
of the clinical symptoms, cartilage destruction and articular inflammation. This coincided 
with elevated pro-inflammatory cytokines, collagen-specific auto-antibody titers and 
increased Th1/Th17 immune responses151,152.  
Osteoarthritis is the most common form of arthritis and is characterized by progressive 
degeneration of the articular cartilage resulting in joint pain, stiffness and functional 
impairment153. In contrast to rheumatoid arthritis, osteoarthritis is not a chronic auto-
inflammatory disease but is caused by cartilage loss as the result of aging, mechanical stress 
and distorted anabolic and catabolic activities by the cartilage chondrocytes. Expression of 
both LXRα and LXRβ was shown to be reduced in cartilage from osteoarthritis patients154,155, 
suggestive of a protective role of LXR in osteoarthritis development. In agreement, LXR 
agonist treatment of human articular cartilage explants reduced cytokine-induced 
proteoglycan degradation and expression of inflammatory mediators in an LXRβ-dependent 
manner154,156. This shows that LXRβ activation reduces matrix degradation in the cartilage 
and might represent an attractive candidate for treatment of osteoarthritis. 
 
4.5 Inflammatory skin disease 
 
Apart from regulation of cholesterol homeostasis in the epidermis, LXR activation also 
stimulates keratinocyte differentiation and improves permeability barrier function157–159. 
Whereas in the human epidermis both LXR isoforms are expressed, in mice the predominant 
isoform expressed in the epidermis is LXRβ157. Aside from their role in epidermal lipid 
homeostasis, LXR activation displays anti-inflammatory properties in several inflammatory 
skin disease mouse models.  
LXR activating ligands were shown to display anti-inflammatory effects in mouse models of 
irritant and allergic contact dermatitis. Topical treatment with LXR agonists reduced ear 
thickness, inflammatory cell recruitment to the epidermis and production of the pro-
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inflammatory cytokines TNFα and IL-1α12,160. In addition to contact dermatitis, LXR was also 
shown to reduce inflammation in a model of IgE-mediated atopic dermatitis. Topical 
administration of synthetic LXR agonists reduced the clinical signs of dermatitis, decreased 
eosinophil infiltration and pro-inflammatory cytokine production161.  
Psoriasis represents another inflammatory skin diseases in which LXR appears to mediate a 
protective role, evidenced by a severely reduced expression of LXRα seen in skin lesions 
from psoriasis patients101,102. Moreover, LXRα knock-down in normal human keratinocytes 
resulted in a genomic profile also observed in psoriatic skin lesions101.   
In summary, LXR activation exerts anti-inflammatory effects in the skin and improves barrier 
function through stimulation of epidermal differentiation and lipid production. As a 
consequence, LXR agonists could serve as a novel therapeutic for inflammatory skin diseases 
such as psoriasis and dermatitis.  
 
4.6 Inflammatory bowel disease 
 
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a 
chronic relapsing disorder of the gastrointestinal tract that is characterized by intestinal 
inflammation and epithelial injury162. A protective role of LXR in the development of IBD is 
implied by the report that LXRβ gene polymorphisms are associated with Crohn’s disease and 
ulcerative colitis21. In addition, expression of both LXR isoforms was found to be suppressed 
in inflamed colon tissue from IBD patients100. Studies in mouse models also revealed a 
protective role of LXR in the development of DSS- and TNBS-induced colitis100. Treatment 
with LXR ligands reduced colitis-related symptoms including body weight loss, rectal 
bleeding and diarrhoea, whereas loss of LXR, in particular of LXRβ, resulted in more severe 
colitis symptoms. The reduced colitis symptoms upon LXR agonist treatment were associated 
with reduced inflammatory cell recruitment to the colon and diminished production of pro-
inflammatory cytokine and chemokines. The anti-inflammatory effect of LXR ligands was 
further confirmed on human colonic epithelial cell lines and was shown to be mediated 
primarily by LXRβ, whereas both isoforms were shown to mediate inflammatory cytokine 
production in the immune cells of the colon after LPS-induced colitis. This shows that by 
suppressing both inflammatory cytokines and chemokine expression in immune cells and 
colonic epithelial cells, LXRs affect the immunopathogenesis of IBD.  
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Table 2 | Overview of effect of LXR activity on infectious and inflammatory diseases. 
 Disease Model Mechanism LXR isoform specificity Reference 
LXR activity is protective 
 atherosclerosis - cholesterol efflux from lipid-loaded   
macrophages 
- repression of pro-inflammatory cytokine 
expression 
- reduced macrophage apoptosis due to 
SPα/AIM upregulation  
 
both 12,113,119,114,163 
 alzheimer’s disease - reduced amyloid-β aggregates (chaperone 
function lipidated apoE) 
- inhibition of microglial inflammation and 
restored phagocytosis 
 
both 82,134–137,140 
 multiple sclerosis - inhibition of Th17 differentiation 
- cholesterol homeostasis in myelin-
producing oligodendrocytes 
 
both 96,94,143,84,148,149 
 lupus-like 
autoimmunity 
- apoptotic cells promote their own clearance 
as well as immune tolerance through LXR 
activation 
 
both 88,89 
 dermatitis - epidermal differentiation and barrier 
function 
- anti-inflammatory 
 
 160,161 
 inflammatory 
bowel disease 
- anti-inflammatory 
 
 
LXRβ 100 
 osteoarthritis - reduced matrix degradation 
- anti-inflammatory 
 
LXRβ 154,156 
 tuberculosis - promote early neutrophilic inflammation 
- increased Th1/Th17 immune response 
 
LXRα 104 
 listeriosis - reduced macrophage apoptosis LXRα 164 
     
LXR activity increases suscecptibility 
 visceral 
leishmaniasis 
- loss of LXR activity is associated with 
enhanced macrophage killing 
 
LXRα 165 
 K. pneumonia 
infection 
- LXR activation impairs neutrophil 
recruitment to lung 
 166 
     
LXR activity is both protective as aggrevating 
 rheumatoid arthritis - loss of LXR activity results in a more 
severe disease 
- LXR activation is associated with both and 
increase and decrease in cartilage destruction 
and joint inflammation 
both 98,99,151,152 
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5. Liver X receptor in infectious diseases 
 
Based on the anti-inflammatory actions of LXR agonists12,13, one would expect LXR 
activation to attenuate the host innate immune response against pathogens causing infectious 
disease. However, LXR activity leads to different outcomes depending on the invading 
pathogen1. 
LXR deficient mice have been shown to be resistant to systemic infection with the 
intracellular protozoan Leishmania chagasi/infantum, a parasite that resides and replicates in 
macrophage phagolysosomes and is the causative agent of visceral leishmaniasis165. The 
increased resistance is primarily associated with loss of the LXRα isoform, and is 
characterized by lower parasite loads in the liver and spleen of the LXRα deficient mice. In 
accordance, loss of LXR activity in bone marrow-derived macrophages resulted in enhanced 
microbicidal activity upon IFNγ-mediated macrophage activation. The enhanced macrophage 
killing correlated with increased NO production and increased gene expression of IL-1β165. 
In contrast, LXRα deficient mice are more susceptible to systemic infection with the 
intracellular bacterial pathogen Listeria monocytogenes164. The increased susceptibility to L. 
monocytogenes was shown to be associated with reduced expression of the LXR target gene 
SPα, identified as having anti-apoptotic function. LXR deficient macrophages displayed 
increased apoptosis upon L. monocytogenes infection correlating with a decreased ability to 
clear the bacteria. In addition, LXR activation was also shown to promote macrophage 
survival during infection by several other bacteria, including the intracellular pathogens 
Bacillus anthracis, Escherichia Coli and Salmonella typhimurium167. These effects correlated 
with a downregulation of several members of the caspase family and other pro-apoptotic 
factors together with an induction of anti-apoptotic regulators including SPα. These data show 
that LXR activation can reduce susceptibility to infectious diseases by reducing macrophage 
apoptosis, an ability often used by intracellular pathogens to escape innate immune responses 
and successfully colonize the host167. In addition to its role in infectious diseases, LXR-
mediated induction of SPα has also been shown in atherosclerotic foam cells and was 
attributed a role in reducing early atherosclerotic lesion development by prevention of 
macrophage apoptosis163.  
Increased susceptibility of LXR deficient mice has also been reported for Mycobacterium 
tuberculosis infection104. The reduced resistance was associated primarily with the loss of the 
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LXRα isoform and was characterized by increased bacterial burden in lung, spleen and liver. 
Reduced resistance was attributed to a defective early neutrophilic airway response along with 
reduced Th1 and Th17 responses in the lungs. This was further confirmed in WT mice that 
upon treatment with LXR agonists displayed a reduced bacterial burden and an increased 
Th1/Th17 response. In contrast to increased resistance to the pulmonary pathogen M. 
tuberculosis, LXR activation impairs pulmonary host defense against extracellular pathogen 
Klebsiella pneumoniae166. The reduced resistance to K. pneumoniae was attributed to an 
impairment of early neutrophil recruitment to the lungs, through inhibition of pulmonary 
TNFα expression and impairment of neutrophil motility. This shows that the role of LXR in 
regulation of neutrophilic lung inflammation appears to be dependent on the type of pathogen. 
Several intracellular pathogens, including Chlamydia pneumonia and M. tuberculosis, convert 
host macrophages into nutrient-rich foam cells168,169. Pathogen-induced foam cell formation 
was shown to result from inhibition of LXR activity through TLR3- or TLR4-mediated IRF3 
signalling170,171. In accordance, treatment with LXR agonists results in cholesterol efflux and 
reduced foam cell formation during macrophage infection with C. pneumonia. While, the 
ability of pathogen-induced IRF3 signalling to inhibit LXR-mediated cholesterol efflux 
provides a strategy for pathogen-induced lipid accumulation, it also identifies how LXR-
mediated transrepression of pro-inflammatory responses might be abolished upon infection, 
enabling an innate antimicrobial immune responses. 
6. Therapeutic use of liver X receptor agonists 
 
The positive regulation of reverse cholesterol transport and the anti-inflammatory properties 
exhibited by LXR, as described in this chapter, make pharmacological LXR activation a 
promising strategy for treating metabolic disorders, chronic inflammatory diseases and 
neurodegenerative diseases. However, systemic LXR agonist treatment also results in 
increased hepatic steatosis and hypertriglyceridemia due to the lipogenic activity of LXR and 
forms the main obstacle in the development of LXR-activating drugs. Seeing as hepatic 
lipogenesis is mainly mediated by the LXRα isoform, which also is the dominant isoform in 
the liver, the prevailing strategy to avoid hepatic lipogenesis has been to develop LXR ligands 
that selectively activate the LXRβ isoform. This is further supported by the observation that 
activation of LXRβ increased reverse cholesterol transport in mice without increasing 
triglyceride production in the liver172. However, the development of LXRβ selective agonists 
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has proven to be difficult because of the highly similar structure between the ligand-binding 
pockets of LXRα and LXRβ. Restricting LXR activation to a specific tissue has also been 
shown to be a good strategy to avoid hepatic side effects. This is demonstrated by increased 
cholesterol efflux173 and protection against atherosclerosis174 by tissue-specific activation of 
LXR in the intestine by the LXR agonist GW6340. Aside from the development of selective 
LXR modulators, either isoform-specific or tissue-specific, another approach is the use of 
endogenous LXR ligands that apart from LXR activation also suppress SREBP processing 
and thus reduce hepatic lipogenesis. 
Anti-inflammatory LXR transrepression has been suggested to not require RXR 
heterodimerization in contrast to LXR transactivation. This supports the notion that ligands 
that dissociate between metabolic transactivation and anti-inflammatory transrepression could 
be used for the treatment of chronic inflammatory diseases without unwanted metabolic side 
effects175. 
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INTRODUCTION  PART 2 | Host-pathogen interactions of the mycobacterial cell wall component mycolic acid 
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1. General structure of mycolic acids 
 
Mycolic acids (MAs) are key components of the cell wall of Corynebacterineae, a distinct 
group of Gram-positive bacteria including the genera Corynebacterium, Rhodococcus, 
Nocardia and Mycobacterium. Mycolic acids are branched long-chain α-alkyl β-hydroxy fatty 
acids (Fig. 1) made up of a mycolic motif that contains a non-functionalised long alkyl chain, 
the corynomycolate chain, and of a meromycolate chain that contains up to two functional 
groups. The genera with the smallest and simplest mycolic acids are Corynebacterium (C28-
C40), Rhodococcus (C30-C54) and Nocardia (C42-C66). In these bacteria the mycolic acids 
function solely as a structural cell wall component conferring the bacteria with a highly 
hydrophobic cell wall1.  
 
 
 
Figure 1 | General structure of mycolic acids from mycobacteria. Different classes and types of 
mycolic acids present in M. tuberculosis. Varying lengths of methylene chains are indicated by a-d. 
Adapted from1. 
 64 | P a g e  
 
In the Mycobacterium species the cell wall contains very complex and large (C60-C90) mycolic 
acids. Mycolic acids from pathogenic mycobacteria, including Mycobacterium tuberculosis, 
can be subdivided in three major classes based on the distal meromycolate group, namely the 
α-mycolic acids (αMA), methoxy-mycolic acids (mMA) and keto-mycolic acids (kMA). Each 
class can then be further split into three types: those containing no double bonds, or 
containing one trans-alkene bond or one cis-alkene bond in the proximal meromycolate group 
(Fig. 1)1. Different mycobacteria contain different complex mixtures of these mycolic acids, 
creating a fingerprint. Even in different strains of M. tuberculosis significant differences in 
mycolic acid composition are seen, though this might also be the result of differences in 
growth conditions which also affect mycolic acid composition. The functional groups of 
mycolic acids profoundly affect their bioactivity and are inserted into the mycolic acid by a 
specific family of S-adenosyl methionine dependent methyltransferases. Genetic manipulation 
of these mycolic acid-modifying enzymes helped to define the exact role these functional 
groups play in the virulence of the bacterium. Cyclopropanation, for instance, has in this way 
been associated with virulence as M. tuberculosis strains lacking cyclopropanation show 
severely reduced virulence in mice2. 
2. Mycolic acids are important components of the cell wall of M. 
tuberculosis  
 
The cell envelope of M. tuberculosis (Fig. 2) consists of three major segments: the plasma 
membrane, the cell wall core which is composed of a peptidoglycan and arabinogalactan layer 
and the outermost layer known as the mycomembrane or the mycobacterial outer membrane 
(MOM). The MOM is a lipid bilayer with mycolic acids as key components. In the first model 
describing the MOM, it was proposed that the MOM was a ≥10 nm thick asymmetric lipid 
bilayer formed by an inner layer of mycolic acids that are covalently bound to the underlying 
arabinogalactan layer and by an outer layer harboring a variety of non-covalently bound lipids 
and glycolipids, including the mycolate esters trehalose mono- and dimycolate (TMM and 
TDM), glucose monomycolate (GMM) and glycerol monomycolate (GroMM)3,4. This 
composition of the MOM was recently revised based on cryo-electron microscopy that 
showed that the MOM was morphologically symmetrical. It was suggested that free 
glycolipids like TDM were not restricted to the outer leaflet but are distributed over both 
leaflets. Despite of the long meromycolate chain of mycolic acids, this model showed that the 
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MOM was only approximately 8 nm thick, leaving two possibilities for the conformation of 
the mycolic acids. If the meromycolate chain has an elongated conformation, it would span 
the entire MOM, leaving space for free lipids to intercalate (Fig. 2 - revised model 1). A 
second possibility is that the meromycolate chain adapts a compact folded conformation (Fig. 
2 - revised model 2). Finally, the surface of M. tuberculosis is coated with a capsular layer 
that is essentially composed of polysaccharides and proteins with only minor amounts of 
lipids3–6. 
 
 
 
Figure 2 | Structural representation of the mycobacterial cell envelope. The plasma membrane is 
covered by a layer of peptidoglycan which is covalently linked to an arabinogalactan layer. The outer 
membrane contains mycolic acids, which are confined to the inner layer, and mycolate esters. Two 
revised models have been described on the structure of the outer membrane. In the first model the 
meromycolate chain of the mycolic acids and the mycolate esters span the entire membrane, in the 
second model the meromycolate chains are folded upon themselves to create a more compact 
structure. Adapted from3,4.  
3. Host-pathogen interactions of mycolic acids 
 
Apart from their role as structural components of the cell wall, mycolic acids are also 
important mediators of host-pathogen interactions. Mycolic acids have been identified as 
important virulence factors that interact with the lipid metabolism of the host to induce foam 
cell formation, creating a nutrient rich environment for bacterial growth7,8. In addition, 
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mycolic acids were shown to be involved in immune recognition of the bacteria, either by  
modulating the innate immune response elicited towards M. tuberculosis7,9 or as important 
lipid antigens in the following adaptive immune response10,11.  The structural complexity of 
the mycolic acids plays an important role both at the level of lipid metabolism modulation and 
of immune recognition. This illustrates that M. tuberculosis can determine the outcome of its 
interaction with the host by modifying its mycolic acid composition.   
 
3.1 Mycolic acids modulate the lipid metabolism of the host cell 
resulting in foam cell development  
 
M. tuberculosis is an obligate intracellular pathogen that resides in the phagosome of the 
macrophage. As these phagosomes represent a nutrient-poor environment, the bacteria 
modulate the host lipid metabolism to induce lipid accumulation, resulting in foam cell 
formation (Fig. 3A). Foam cells are macrophages that are filled with host-derived lipids 
stored in organelles known as lipid droplets or lipid bodies (LB) and their development during 
M. tuberculosis infections has been attributed to mycolic acids. 
 
 
 
Figure 3 | Mycobacterium tuberculosis induces foam cell formation. (A) A peripheral blood 
monocyte infected with Mtb H37Rv displaying accumulation of lipid bodies (LB) at day 11 post-
infection. Several Mtb-containing phagosomes are in close vicinity to a LB. Electron microscope 
picture from8. (B) Lipid bodies are taken up by bacilli-containing phagosomes either (1) in an 
autophagy-like manner or (2) through fusion between the membrane of the lipid droplet and the 
membrane of the phagosome. 
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A prior study from our lab by Korf et al. showed that liposome-formulated mycolic acids are 
taken up by macrophages and induce the formation of cholesterol-rich foamy macrophages7. 
This was supported by a following study that demonstrated foam cell formation to be 
specifically induced by oxygenated mycolic acids, i.e. methoxy-MA and keto-MA, which are 
associated with pathogenic mycobacteria8,12. In M. tuberculosis infected macrophages, the 
lipid droplets that are formed are taken up by bacilli-containing phagosomes, either in an 
autophagy-like manner8 or through fusion of the lipid droplet and the phagosome13, thus 
delivering lipids to the bacteria (Fig. 3B). It is already well documented that M. tuberculosis 
can use cholesterol as its sole carbon source14,15 and that bacteria growing inside the 
phagosome of macrophages show an induced expression of genes encoding enzymes required 
for lipid and fatty acid metabolism15,16. This shows that mycolic acids influence the lipid 
metabolism of the host to induce foam cell formation creating a nutrient reservoir for the 
bacteria. Apart from a role as nutrient reservoir, foam cell formation has also been involved in 
granuloma development8 and eicosanoid production17. 
Despite of abundant evidence that mycolic acids function as important virulence factors by 
modulating the lipid metabolism of the host, relatively little is known about how these 
mycolic acids interact with the host at molecular level. Macrophages classically convert into 
foam cells through a dysregulation in the balance between influx and efflux of cholesterol. 
Cholesterol is transported to peripheral macrophages in low density lipoproteins (LDL) that 
are taken up by the cell through the LDL receptor, or in the oxidized form, through scavenger 
receptors SRA and CD36. Cholesterol taken up by the cell is esterified and sequestered in 
lipid droplets. Cholesterol efflux is mediated by the ATP-binding cassette transporters A1 and 
G1 (ABCA1 and ABCG1) that load the cholesterol on high density lipoproteins (HDL) that 
transport the cholesterol to the liver, a mechanism also known as reverse cholesterol transport. 
These processes are regulated by the lipid sensing nuclear receptors liver X receptor (LXR) 
and peroxisome proliferator-activated receptor γ (PPARγ). Mycobacterial-induced foam cell 
formation is associated with an increased expression of PPARγ18 and mycobacterial lipids 
have been shown to activate PPARγ transcription19,20. Activation of PPARγ results in an 
increase in mycobacterial foam cell formation and PPARγ deficiency results in impaired 
mycobacterial foam cell formation and impaired mycobacterial growth18,20,21. This identifies 
the nuclear receptor PPARγ as a positive regulator of mycobacterial foam cell formation and 
growth and supports the hypothesis that activation of PPARγ by mycobacterial lipids 
promotes virulence by inducing foam cell formation. A direct role for LXR in mycobacterial 
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foam cell formation has not been reported. However, mice deficient for LXR show 
spontaneous foam cell formation22 as well as an increased susceptibility to M. tuberculosis 
infection characterised by reduced mycobacterial growth23. This suggests that LXR functions 
as a negative regulator of mycobacterial foam cell formation and mycobacterial growth, 
identifying this nuclear receptor as an interesting target for tuberculosis treatment23.  
 
3.2 Mycolic acids modulate innate immunity and are important 
antigens in adaptive immunity  
 
M. tuberculosis is transmitted when a person with active pulmonary tuberculosis sneezes or 
coughs, creating an infectious aerosol that can be inhaled by a healthy bystander. After 
inhalation of infectious aerosol droplets, the first cells to encounter the bacteria are the 
alveolar macrophages. Immune recognition of M. tuberculosis is mediated by binding of 
pathogen-associated molecular patterns (PAMPS), such as the mycobacterial cell wall 
components lipoarabinomannan (LAM) and TDM, to pattern-recognition receptors (PRR) 
expressed on innate immune cells like macrophages and dendritic cells. Activation of the 
innate immune system enables the development of a long lasting adaptive immune response 
towards M. tuberculosis, characterised by Th1-dependent macrophage activation.  
 
Mycolic acids modulate host innate immune responses 
In a first report of our lab, Korf et al. described the activation of macrophages by mycolic 
acids. A mixture of mycolic acids isolated from the virulent M. tuberculosis strain H37Rv 
induced host innate airway responses characteristic of M. tuberculosis infection. When 
administered to the airways, liposome-formulated mycolic acids were taken up by alveolar 
macrophages and induced transient neutrophilic airway inflammation accompanied by IL-12 
and IL-6 production. This shows that mycolic acids are recognised by macrophages as 
PAMPs and elicit an innate immune response7. The receptor by which mycolic acids are 
recognised by the host cell is not known and while toll-like receptor 2 (TLR2) and 4 (TLR4) 
are both involved in recognition of M. tuberculosis, they did not mediate mycolic acid 
recognition7. 
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In addition to macrophage activation, mycolic acids also conditioned macrophages to show a 
Th1 bias to cellular immunity upon stimulation with a secondary inflammatory stimulus7 and 
inhibited non-protective Th2-dependent immunity as indicated by their suppression of allergic 
airway inflammation in a mouse model of asthma24. These observations indicate that mycolic 
acids actively contribute to the development of protective Th1-driven cellular immunity and 
the clearance of the pathogen. 
As mycolic acid composition seems to be closely related to virulence, a study of our lab by 
Vander Beken et al. addressed the inflammatory activity of single mycolic acids. Hereto, 
synthetic mycolic acid compounds of individual mycolic acid classes differing in their 
proximal cyclopropane stereochemical configuration were used25–31. Analysis of mycolic 
acid-elicited lung inflammation revealed a strong dependence of the inflammatory response 
on mycolic acid stereochemistry and functional groups. Whereas cis αMA was inert, 
oxygenated mycolic acids with cis-cyclopropane stereochemistry elicited mild (keto) to solid 
(methoxy) inflammatory responses. In the trans-cyclopropane orientation, the oxygenated 
mycolic acids partially lost inflammatory activity (methoxy) or reverted to exerting anti-
inflammatory activity (keto)9. These differential innate immune activities of single mycolic 
acid-isomers identify a novel means for M. tuberculosis to steer host immune responses 
during infection by remodelling the mycolic acid composition of its cell wall. 
 
Mycolic acids are important lipid antigens involved in the adaptive immune 
response toward M. tuberculosis infection  
The ability of the adaptive immune system to eradicate a pathogen depends on pathogen 
uptake by antigen presenting cells (APCs), like macrophages and dendritic cells, and 
subsequent presentation of pathogen-derived antigens to effector T cells. While protein 
antigens are presented by major histocompatibility complex (MHC) proteins, lipid antigens 
are presented by the CD1 family of MHC-like molecules. Lipid antigens bind to CD1 
molecules with their alkyl chains buried in the hydrophobic groove of the CD1 molecule and 
expose their polar lipid headgroup, leaving it accessible for recognition by the T cell receptor. 
Group I CD1, comprising the human CD1a, CD1b and CD1c, present lipid antigens with long 
hydrophobic tails and have been implicated in antimycobacterial immunity. Group II CD1 
present glycosylated lipids with shorter hydrophobic tails and comprises CD1d. While group I 
CD1 present lipids to CD4 and CD8 T cells, group II CD1 only presents to NK T cells. 
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Rodents do not harbour group I CD1 molecules and only group II CD1d is found on 
APCs32,33. 
Mycolic acids have been shown to be presented by CD1b on human dendritic cells10,32 and 
CD1b restricted T cells have been identified in the blood and the lungs of the majority of TB 
patients10 (Fig. 4). Group I CD1-restricted effector T cells produce high levels of the Th1 
cytokines IFNγ and TNFα, which activate the microbicidal function of macrophages. In 
addition, group I CD1-restricted T cells are potent cytotoxic T cells which upon antigen 
recognition release cytolytic granules containing perforin and granulysin, which lyse the 
infected cells and exert direct microbicidal activity10,32. This identifies mycolic acids as 
important lipid antigens involved in the cellular immune response toward M. tuberculosis 
infection. 
 
 
 
Figure 4 | Mycolic acid presentation by CD1b on dendritic cell to CD1b-restricted T cell. 
Dendritic cells (DCs) that are infected with M. tuberculosis present mycolic acids on the surface 
bound to CD1b. CD1b-restricted T cells that recognise the mycolic acid are activated and secrete 
cytolytic granules containing perforin and granulysin, which lyse the infected cell. They also produce 
IFNγ and TNFα, which activate the microbicidal functions of macrophages. Restricted to human as 
rodents do not express group I CD1b molecules. Adapted from32. 
 
While the role of T cells in antimycobacterial immunity has been well established, the role of 
humoral immunity is not clearly understood and has been generally considered as 
insignificant in contributing to protective immunity against M. tuberculosis. However, 
accumulating evidence suggests that B cells and humoral immunity can modulate the immune 
response to various intracellular pathogens, including M. tuberculosis34,35. The latter is 
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suggested by the presence of anti-mycolic acid IgG antibodies in the sera of tuberculosis 
patients. When comparing the various mycolic acid subclasses, methoxy-mycolic acids were 
shown to be the most antigenic as compared to α- and keto-mycolic acids11,36. Antigenicity 
was further shown to be dependent on the structure of the mycolic motif and on the structure 
and stereochemistry of the functional groups in the meromycolate chain36. This identifies 
specific subclasses of mycolic acid as important antigens in the humoral immune response 
towards M. tuberculosis infection. As such, antibodies specific for mycolic acids were 
investigated as potential biomarker for diagnosis of tuberculosis. However, cross-reactivity of 
patient serum antibodies between mycolic acids and cholesterol was observed, most likely due 
to the cholesteroid nature of mycolic acids37.   
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INTRODUCTION PART 3 | Allergic eosinophilic asthma 
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1. Definition and asthma phenotypes 
 
Asthma is a chronic lung disease that presents as recurrent episodes of wheezing, shortness of 
breath and chest tightness. These symptoms are associated with airway narrowing, airway 
hyper-reactivity and airway inflammation. 
The dominant feature of asthma that leads to clinical symptoms is excessive airway 
bronchoconstriction after exposure to an airborne allergen. However, there are also several 
non-allergic triggers known such as cold air, exercise, stress and aspirin.  
Asthma is a heterogeneous disease with different subgroups or phenotypes (Table 1)1–3. The 
division of asthma into phenotypes is based on clinical characteristics (severity, fixed airflow 
limitation, age at onset), factors that associate with or trigger asthma (allergic, aspirin, 
obesity) and pathobiological characteristics, including eosinophilic and neutrophilic 
inflammation. Even though the topic is still controversial a growing understanding of the 
distinct asthma phenotypes will prove to be essential for predicting the clinical response to 
various asthma therapies and for the development of individualized treatment. 
 
 
Table 1 | Asthma phenotypes. Adapted from1,3,4. 
 
 Natural 
history 
Clinical and 
physiological 
features 
Pathobiology and 
biomarkers Response to therapy 
Th2-high phenotype 
Early-onset 
allergic 
early onset 
mild - severe 
allergic disease 
(atopic) 
IgE, Th2 cytokines, 
eosinophils corticosteroid-responsive 
Late-onset 
eosinophilic 
adult onset 
often severe 
less allergic 
(non-atopic) 
Th2 cytokines, 
eosinophils 
corticosteroid-refractory, 
responsive to anti IL-5 
treatment 
Exercise-
induced  
mild, follows 
exercise 
eosinophils, mast 
cell activation, Th2 
responsive to anti IL-9 
treatment 
Th2-low phenotype 
Obesity-
related adult onset 
common in 
women 
lack of Th2 
markers 
corticosteroid-refractory, 
responsive to weight loss 
Neutrophilic   Th17, neutrophils  
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In this dissertation we will focus on allergic eosinophilic asthma which represents the 
majority of asthma cases. This asthma phenotype typically develops in childhood or 
adolescence and is defined by a Th2-dominant inflammatory process with both airway and 
blood eosinophilia. These asthma patients are atopic, which is defined by a predisposition to 
mount an immunoglobulin type E (IgE) immune response and often is associated with a 
history of allergic disease. Early-onset asthma can present as mild to severe disease. Most 
patients with mild allergic asthma respond to inhaled corticosteroids, but in patients with 
more severe allergic asthma this treatment tends to be less effective1–4. 
2. The hygiene hypothesis 
 
The global prevalence of asthma and allergic diseases has increased dramatically over the last 
few decades, particularly in the Western world5,6. The increase in allergy contrasts strongly 
with a reduced prevalence of infectious diseases, a result of improved public health measures, 
disease treatment, vaccination programmes and hygiene. This is associated with a 
corresponding decreased exposure to parasitic infections and to other pathogenic and non-
pathogenic microorganisms. Such infections usually promote the normal development of 
immune responses (with a bias towards Th1 cells rather than Th2 cells) and favour the 
development of appropriate control of potentially harmful immune responses by various 
populations of regulatory T cells. However, as exposure to infections is reduced, and exposure 
to certain otherwise harmless environmental allergens is increased, there is a propensity for 
genetically predisposed individuals to develop Th2 cell-type responses to a variety of 
common environmental allergens. This is commonly referred to as the hygiene hypothesis7,8. 
3. Asthma pathogenesis 
 
The pathology of allergic eosinophilic asthma is characterised by infiltration of inflammatory 
cells into the airways, among which CD4+ T cells, eosinophils and mast cells predominate. 
The chronic inflammatory response involves cross-talk between the airway epithelium, innate 
immune cells and adaptive immune cells. This cross-talk is mediated by Th2 cytokines. 
Persistent inflammation in the airways eventually leads to airway remodelling and airway 
hyper-reactivity (AHR). 
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Allergen sensitization in the airways 
The airway epithelium provides an important barrier between the host and the environment 
and represents the first line of defense against microorganisms and allergens. Allergens can 
either be sampled by dendritic cells in the airway lumen, or can enter the tissue through a 
disrupted epithelium or through protease activity, where they are recognised by submucosal 
dendritic cells9. Upon recognition of the allergen, dendritic cells maturate and migrate to the 
draining lymph nodes where they present peptides derived from the processed allergen to 
naïve T cells. The presence of IL-4 drives Th2 cell differentiation. These Th2 cells produce 
IL-4 and IL-13, which drives B cell differentiation and isotype switching resulting in IgE 
antibody production. Allergen-specific IgE binds to the high-affinity receptor for IgE (FcεRI) 
on tissue-resident mast cells, thereby rendering the individual sensitive to subsequent 
exposure to the allergen.  
Apart from a strict barrier function, epithelial cells also express several pattern recognition 
receptors (PRRs), enabling them to detect environmental stimuli and secrete cytokines, 
chemokines and antimicrobial peptides that attract and activate innate and adaptive immune 
cells. Recent studies have demonstrated that epithelial cell activation is a key triggering event 
in the recognition of inhaled allergens that activates the local network of dendritic cells, which 
coordinate the subsequent immune response9. Activation of airway epithelial cells in response 
to inhaled allergens or to epithelial damage, leads to release of a variety of Th2 cytokines, 
such as thymic stromal lymphopoietin (TSLP), GM-CSF, IL-25, IL-33 and IL-1 family 
members10. These cytokine contribute to DC activation and drive the Th2 immune response 
through activation of natural-killer T cells, mast cells, eosinophils, and basophils9. In addition, 
they stimulate the newly discovered innate lymphoid cells (ILC2) that secrete Th2 cytokines 
(mainly IL-13 and IL-5) in response to airway epithelial damage11.  
 
Early-phase effector reaction 
The early-phase reaction occurs 30 to 60 min after exposure of a sensitized individual to the 
allergen and comprises a type I hypersensitivity reaction which mainly constitutes of mast cell 
activation. Recognition of the allergen by FcεRI-bound IgE on mast cells induces FcεRI 
aggregation, which activates the mast cell to secrete inflammatory mediators. Preformed 
mediators such as histamine are released via degranulation of cytoplasmatic granules. 
Activated mast cells also secrete newly synthesized lipid mediators, derived from the 
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catabolism of membrane-associated arachidonic acid into prostaglandins (PG) and 
leukotrienes (LT). The rapidly secreted mediators result in bronchoconstriction and increased 
mucus production, which results in airflow obstruction and wheezing. In addition, increased 
vascular permeability and release of inflammatory cytokines (TNFα) and chemokines (CCL2) 
results in inflammatory cell recruitment contributing to the transition to the late-phase 
reaction8. 
 
Late-phase effector reaction 
Late-phase effector reactions develop two to six hours after the initial allergen challenge and 
involve the recruitment of innate and adaptive leukocytes from the circulation by mast cell-
derived cytokines and chemokines. The recruited immune cells, mainly Th2 cells and 
eosinophils, become the main producers of inflammatory mediators, such as IL-4, IL-5, and 
IL-13, which coordinately regulate many aspects of allergic inflammation8,10,12. IL-4 promotes 
B cell activation and IgE isotype switching, upregulation of adhesion molecules on the 
inflammatory epithelium, production of eotaxin, and the development of AHR and goblet cell 
hyperplasia. Most of these functions can also be mimicked by IL-13 due to receptor sharing as 
both IL-4 and IL-13 can signal through a heterodimer composed of the IL-4Rα and the IL-
13Rα1. IL-5 is a cytokine critical to eosinophil growth, maturation, activation, and survival. 
Differentiation of lineage-committed eosinophil precorsor (eoP) cells into mature eosinophils 
in the bone marrow is regulated by the cytokines IL-5, IL-3 and GM-CSF. Expression of the 
chemokine receptor CCR3 is induced during eosinophil development, and serves as the 
primary chemokine receptor responsible for eosinophil trafficking to the airways. Eosinophil 
migration from the blood to the airway is dependent on chemokine gradients, most notably 
eotaxin and RANTES.  
 
Chronic stage of allergic asthma 
When allergen exposure is continuous or repetitive, inflammation persists. Persistent airway 
inflammation, tissue injury and subsequent abnormal repair lead to structural changes in the 
airway walls known as airway remodelling. These structural changes are characterized by 
epithelial cell alterations, subepithelial fibrosis, submucosal gland hyperplasia, increased 
airway vascularization and increased airway smooth muscle (ASM) mass. Airway 
remodelling in asthma patients contributes to AHR and airflow obstruction13. 
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Figure 1 | Asthma pathogenesis. Allergens are sampled by dendritic cells (DCs) which promote Th2 
cell differentiation. Allergens are also recognised by pattern recognition receptors (PRRs) on epithelial 
cellsand results in the secretion of Th2 cytokines including thymic stromal lymphopoietin (TSLP), IL-
25 and IL-33. These cytokines promote DC maturation and activate type 2 innate lymphoid cells 
(ILC2). Production of IL-4 by Th2 cells promotes B cell differentiation and IgE isotype switching. IgE 
antibodies bind FcεRI on mast cells, arming these cells for allergen recognition, upon which these 
cells will drive the early-phase effector reaction of the asthma response. Both IL-4 and IL-13 promote 
mucus hyper-secretion from goblet cells and airway hyper-reactivity. IL-5 drives eosinophil 
development in the bone marrow, together with IL-3 and GM-CSF. Eosinophils develop from lineage 
committed eosinophil progenitors downstream from the granulocyte monocyte progenitor (GMP) and 
the common myeloid progenitor (CMP). Mature eosinophils express the chemokine receptor CCR3, 
enabling them to leave the bone marrow and travel to the airways following a chemokine gradient, 
most notably of eotaxins and RANTES.  
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PART 1 
Liver X receptors (LXRs) are integrators of cholesterol homeostasis and inflammatory 
signalling. This crosstalk has made LXRs promising therapeutic targets in the treatment of a 
broad range of chronic inflammatory diseases, including lipid disorders, autoimmune diseases 
and neurodegenerative diseases. However, the role of LXRs as inflammatory mediators 
remains elusive with both pro-inflammatory and anti-inflammatory properties being reported, 
dependent on the diseases context. In this dissertation, we addressed the involvement of LXR 
activity in allergic eosinophilic asthma. Only a limited amount of studies have been done on 
the subject and report contradictory outcomes of LXR activation on respiratory function. 
Here, we aimed to dissect the role of LXR activity in airway inflammation, lying at the basis 
of asthma pathogenesis. We provide evidence for a contributory role of LXR activity in the 
development of eosinophilic inflammation through positive regulation of the expression of 
Th2-related cytokines. In addition, we hypothesize that the positive contribution of LXR 
activity to allergic asthma could explain the increase in symptom severity seen in 
hypercholesterolemic asthma patients.  
 
PART 2 
Mycolic acids are highly hydrophobic branched long-chain α-alkyl β-hydroxyl fatty acids 
present in the outer membrane of Mycobacterium tuberculosis. Apart from a structural role, 
mycolic acids are also important mediators of host-pathogen interactions and this feature is 
strongly dependent on their structural complexity, which is determined by the variable 
functional groups in the meromycolate chain. In the second part of this dissertation, we 
addressed the influence of single synthetic mycolic acids, representing the naturally occurring 
structures, on the development of anti-mycobacterial adaptive immune responses after 
immunization.  
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1. Cholesterol-sensing liver X receptors contribute to the 
development of Th2-driven eosinophilic asthma in mice  
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1.1 Abstract 
 
Liver X receptors (LXRs) are nuclear receptors that function as cholesterol sensors and 
regulate cholesterol homeostasis. High cholesterol has been recognized as an important risk 
factor in asthma, though the exact mechanism of this linkage is not known. To explore the 
linkage between cholesterol homeostasis and asthma we investigated whether LXR may 
contribute to a mouse model of Th2-driven eosinophilic asthma. Mice deficient for both LXR 
isoforms, LXRα and LXRβ (LXRα-/-β-/-), displayed reduced airway inflammation, airway 
elastance and goblet cell hyperplasia as compared to wild type mice. Serum levels of allergen-
specific IgE were slightly increased in LXRα-/-β-/- mice and thus did not explain the reduced 
airway inflammation. Instead, we found that LXR activity contributed to airway inflammation 
through promotion of type 2 cytokine production as LXRα-/-β-/- mice showed reduced protein 
levels of IL-5 and IL-13 in the lungs. The latter may reflect reduced numbers of lung CD4+ T 
cells that also expressed less IL-5, IL-13 and IL-4 mRNA. Next to a local reduction of Th2-
driven eosinophilic inflammation in the lungs, LXRα-/-β-/- mice also displayed less eosinophils 
in the blood and lower IL-5 levels in the serum, suggesting LXR contributes to eosinophil 
development during asthma. LXRα-/-β-/- bone marrow chimeras reproduced the inflammatory 
phenotype of LXRα-/-β-/- mice, thus demonstrating that leukocytes mediate the regulatory role 
of LXR in asthma. In conclusion, these observations demonstrate that the cholesterol 
regulator LXR acts as a positive regulator of eosinophilic asthma in mice, contributing to 
airway inflammation through regulation of Th2 cytokine production in leukocytes.  
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1.2 Introduction 
 
Asthma is a chronic disease of the airways that presents as recurrent episodes of wheezing, 
shortness of breath, chest tightness and coughing. These symptoms are associated with airway 
inflammation, airway remodelling and airway hyper-responsiveness (AHR). Most commonly 
asthma is an allergic disorder associated with eosinophilic inflammation driven by allergen-
specific IgE antibodies and Th2 cell populations1,2. According to the World Health 
Organization, 235 million people currently suffer from asthma, most of them children3. The 
prevalence of asthma is the highest in developed countries, but the disparity is narrowing due 
to rising prevalence in low and middle income countries as they adopt a more Western-type 
lifestyle4. One of the main objectives in the strategy to prevent and control asthma is to 
analyse its determinants and monitor trends3. Dyslipidemia, characterized by high cholesterol 
levels in the blood, has gained interest as a risk factor for asthma over the last years. Several 
epidemiological studies have shown a positive association between dyslipidemia and the 
development of asthma both in children and adults5–10. In 2008, the global prevalence of high 
cholesterol among adults was 39% and the highest prevalence was observed in developed 
countries11.  
Liver X receptors (LXR) are a subset of nuclear receptors that regulate whole body and 
cellular lipid and cholesterol metabolism12. While the inducible isoform, LXRα, is highly 
expressed in organs involved in lipid metabolism such as the liver, adipose tissue, and 
macrophages, the LXRβ isoform is expressed ubiquitously at a moderate level. LXRs form 
heterodimers with the retinoid X receptor and regulate the expression of genes containing 
LXR-response elements. LXRs act as cholesterol sensors that upon binding of oxidized 
cholesterol derivatives promote transcription of genes involved in reverse cholesterol 
transport, such as the lipid transporters ATP-binding cassette transporter A1 and G1 
(ABCA1/ABCG1), lipid carrier proteins like apolipoprotein E (apoE), and receptors involved 
in lipid uptake such as scavenger receptor BI (SR-BI) and low density lipoprotein receptor 
(LDL-R). Apart from their role in lipid and cholesterol metabolism, LXRs are increasingly 
emerging as inflammatory mediators, either repressing or promoting innate and adaptive 
immune responses in different infectious and inflammatory diseases13–16. Owing to their 
ability to sense increased cholesterol levels and to modulate inflammatory signalling, LXRs 
pose as a potential molecular regulator at the basis of the association between cholesterol and 
asthma. An important feature of allergic disorders, including asthma, is the production of 
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allergen-specific IgE antibodies. Activation of LXR has been shown to negatively regulate 
IgE production through inhibition of B cell differentiation17. In addition, LXR reduced IgE-
mediated mast cell degranulation by downregulation of FcεRI expression on mast cells18. 
Airway remodelling and airway hyper-responsiveness (AHR) constitute another main feature 
of asthma which appears to be modulated by LXR activity. In a first study, LXR agonist 
treatment resulted in an increase in AHR to inhaled metacholine together with a thickening of 
the airway smooth muscle (ASM) mass19. In contrast, a more recent study showed a decrease 
in AHR to inhaled metacholine upon LXR activation. This coincided with a reduced ASM 
thickness and reduced goblet cell hyperplasia20. 
In this study, we used LXR deficient mice to elucidate the role of LXRs in the development of 
eosinophilic asthma. We show that in a Th2-driven mouse model, eosinophilic airway 
inflammation is attenuated in mice deficient for both LXR isoforms. In addition, we 
demonstrate that the reduced airway inflammation upon loss of LXR activity is associated 
with reduced expression of type 2 cytokines in the lungs and blood and is attributable to a 
defect in the haematopoietic cells as determined by bone marrow transplant studies.  
 
1.3 Results 
 
LXR is a positive regulator of eosinophilic airway inflammation  
 
To investigate the potential role of LXRs in asthma, we examined LXR deficient mice in an 
eosinophilic asthma mouse model. Mice were sensitized against ovalbumin (OVA) by 
intraperitoneal (i.p.) injection with OVA/alum at day 0, 7 and 14. At day 28, mice were 
exposed to nebulized OVA for six consecutive days which resulted in inflammatory cell 
infiltration in the lungs. Eosinophils were the most abundant cell type in the bronchoalveolar 
lavage (BAL) next to other inflammatory cells such as T cells and alveolar macrophages 
(AM) (Fig. 1A), as revealed by flow cytometry-based differential cell counting (Fig. S1A). 
Mice deficient for both LXR isoforms (LXRα-/-β-/-) showed a decrease in overall airway 
inflammation, with a 2-fold reduction in eosinophil numbers in the BAL as compared to WT 
mice. Also for the other inflammatory cells present in the lungs a decrease in cell numbers 
was seen in LXRα-/-β-/- mice. This reduction in eosinophilic inflammation was associated with 
the loss of both the LXR α- and β-isoform since eosinophil numbers in the lungs of LXRα-/- 
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and LXRβ-/- mice were identical (Fig. S1B) or near identical (Fig. S1C) to the cell numbers 
observed in WT mice. Because loss of a single isoform was compensated by the other, all 
following experiments were performed on mice deficient for both isoforms (LXRα-/-β-/-). 
Reduced airway eosinophilia in LXR deficient mice was apparent already early in the allergic 
inflammatory response, after two consecutive aerosol exposures, and persisted at all time-
points assessed (Fig. 1B). After six OVA aerosols, eosinophil number in the BAL of LXRα-/-
β-/- mice levelled off to a plateau, whereas in WT mice eosinophil numbers in the BAL still 
increased with additional OVA aerosol exposures.  
In addition to airway inflammation, OVA sensitization and subsequent OVA challenge lead to 
the development of airway hyper-reactivity (AHR). We assessed AHR of unchallenged and 
OVA challenged WT and LXRα-/-β-/- mice by measuring the elastic resistance of the airways 
to aerosolized metacholine (MCh) 24 h after the last of six daily OVA aerosols. As expected, 
OVA challenged mice displayed increased airway elastance as compared to unchallenged 
mice and elastance increased upon exposure to an increasing dose of MCh. The airway 
elastance seen in the OVA challenged LXR deficient mice was significantly lower as that 
seen in OVA challenged WT mice, indicative of reduced stiffness of the lungs (Fig. 1C).  
Excessive mucus production, resulting from goblet cell hyperplasia, is characteristic of airway 
remodelling in asthma. The number of mucus-producing goblet cells was reduced in OVA 
challenged LXR deficient mice in comparison to WT mice, as assessed by PAS staining (Fig. 
1D).  
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Figure 1 | LXR deficient mice display reduced airway inflammation, airway elastance and goblet 
cell hyperplasia in an eosinophilic asthma model as compared to WT mice. WT and LXRα-/-β-/- 
mice were sensitized against OVA together with alum via the i.p. route and then challenged with 
aerosolized OVA. (A) Differential cell counts in the BAL were measured by flow cytometry 24 h after 
six OVA aerosols. (B) Eosinophils in the BAL were measured by flow cytometry 24 h after 2 to 8 
consecutive OVA aerosols. (C) Mice were exposed to increasing doses of metacholine 24 h after six 
OVA aerosols, and airway elastance was measured. (D) Mucus production was evaluated by PAS 
staining of lung paraffin sections of mice exposed to six OVA aerosols. Data are shown as mean ± SD, 
n = 5 to 7 mice per group. The results show one representative experiment out of at least two 
independent experiments. Statistical analysis between two groups was performed using a Mann-
Whitney test. Differences in airway elastance were analysed by two-way ANOVA with repeated-
measures. Significant p-values were ranked as p < 0,05 (*), p < 0,01 (**), and p < 0,001 (***). 
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LXR deficiency promotes increased IgE levels after allergen challenge  
 
The OVA/alum mouse model is an allergic asthma model driven by OVA-specific IgE 
antibodies, which are produced by sensitized allergen-specific B cells. In order to verify the 
consequences of LXR deficiency on IgE production, we measured the OVA-specific IgE 
levels in the serum of OVA/alum sensitized mice before and after OVA challenge. As shown 
in Fig. 2A serum levels of OVA-specific IgE did not differ between sensitized WT and 
LXRα-/-β-/- mice before exposure to nebulized OVA. This indicates that LXR deficiency did 
not interfere with the sensitization of the mice to the allergen. A quantification of OVA-
specific IgE serum levels in mice that were exposed to nebulized OVA showed low levels of 
OVA-specific IgE in the beginning of the asthma response that gradually increased with 
increasing exposures to OVA aerosol. LXRα-/-β-/- mice showed a trend towards increased 
levels of OVA-specific IgE compared to WT mice, reaching statistical significance at 6 and 8 
OVA challenges (Fig. 2B). Thus in mice deficient for LXR activity, a decreased allergic 
airway inflammation goes along with increased OVA-specific IgE levels in the blood. 
 
 
Figure 2 | LXR deficient mice show an increase in OVA-specific IgE levels in the blood after 
multiple OVA challenges as compared to WT mice. After OVA sensitization of WT and LXRα-/-β-/- 
mice, blood was collected either (A) before challenge with OVA aerosol or (B) 24 h after challenge 
with 2 to 8 daily OVA aerosols. Serum titers of OVA-specific IgE were measured by ELISA. Data are 
shown as mean ± SD, n = 5 to 10 mice per group. The results show one representative experiment out 
of at least two independent experiments. Statistical analysis between two groups was performed using 
a Mann-Whitney test. Significant p-values were ranked as p < 0,05 (*), p < 0,01 (**), and p < 0,001 
(***). 
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Figure 3 | LXR deficient mice show a decrease in Th2 cytokine expression in the lungs as 
compared to WT mice. WT and LXRα-/-β-/- mice were sensitized against OVA together with alum via 
the i.p. route and then challenged with 2 to 8 consecutive OVA aerosols. BAL was performed and 
CD4+ cells were isolated from the lung 24 h after the indicated OVA aerosol. Expression of (A) Th2-
associated cytokines (IL-5, IL-13, IL-4) and (B) transcription factors (GATA3 and STAT6) in the 
CD4+ cells of the lung were determined by qPCR. The qPCR analysis was performed on normalized 
numbers of CD4+ cells. (C) The number of CD4+ T cells in the BAL was measured by flow cytometry. 
(D) Cytokine levels of IL-5 and IL-13 in the BALF were measured by luminex analysis. Data are 
shown as mean ± SD, n = 5 to 7 mice per group. The results show one representative experiment out 
of two independent experiments. Statistical analysis between two groups was performed using a 
Mann-Whitney test. Significant p-values were ranked as p < 0,05 (*), p < 0,01 (**), and p < 0,001 
(***). 
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LXR promotes type 2 cytokine production in allergen challenged lungs  
 
Eosinophilic infiltration in the lungs is driven by CD4+ Th2 cells through production of the 
type 2 cytokines IL-4, IL-5 and IL-13. We investigated the effect of LXR deficiency on local 
production of type 2 cytokines by looking at the cytokine expression pattern of CD4+ T cells 
in the lungs after 2 to 8 consecutive daily OVA aerosols. The mRNA levels of IL-5, IL-13 and 
IL-4 were upregulated after 2 to 4 OVA aerosol challenges in WT mice and to a lesser extent 
in CD4+ T cells of LXRα-/-β-/- mice (Fig. 3A). In contrast, the mRNA levels of the Th2-
regulating transcription factors GATA3 and STAT6 were unaltered between WT and LXR 
deficient CD4+ T cells (Fig. 3B), thus indicating that the nature of the Th2 cell response was 
not altered by the LXR deficiency. The lack of expression of mRNA for Th1- and Th17-
associated cytokines and transcription factors further corroborated the unaltered Th2 nature of 
the allergic response in LXRα-/-β-/- mice (data not shown). Finally, in line with our previous 
observations, reduced numbers of CD4+ T cells were present in the BAL of LXRα-/-β-/- mice 
(Fig. 3C). Reduced numbers of Th2 cells along with reduced cytokine expression by the cells 
may very well explain the pronounced drop in IL-5 and IL-13 protein levels observed in the 
BALF of LXRα-/-β-/- mice (Fig. 3D). Protein levels of IL-4 were not detectable in the BALF.  
 
 
LXR deficiency results in a systemic reduction in eosinophil numbers and reduced IL-5 levels 
in the blood, revealing a role in eosinophil development 
 
Eosinophilic airway inflammation is the combined result of an increased differentiation in the 
bone marrow and an increased migration of the eosinophils through the blood to the lungs. To 
verify whether the reduced eosinophil counts seen in LXRα-/-β-/- mice are confined to the 
lungs or reflect a deficiency already at the systemic level, we looked at eosinophil numbers in 
the blood after 2 to 8 consecutive daily OVA aerosols. In line with an increase in local 
eosinophilic airway inflammation, the frequency of eosinophils in the blood showed a strong 
increase at day 4 of OVA exposures, reaching a plateau after day 6 (Fig. 4A). LXR deficient 
mice also showed an increase in blood eosinophil numbers from day 4 on. However, 
compared to WT mice, a significantly lower plateau value is observed.  
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Eosinophils develop from precursor cells in the bone marrow under the influence of IL-5, 
GM-CSF and IL-321,22. The protein levels of IL-5 in the serum were strongly reduced in 
LXRα-/-β-/- mice as compared to WT mice (Fig. 4B). Levels of GM-CSF and IL-3 were either 
not detected in the serum or no differences were observed between WT and LXRα-/-β-/- mice 
(data not shown). The systemic reduction in eosinophil numbers in the blood of LXRα-/-β-/- 
mice after exposure to six OVA aerosols, together with reduced levels of IL-5 in the serum is 
indicative of an LXR-mediated effect on eosinophil differentiation in the bone marrow.  
 
 
 
Figure 4 | LXR deficient mice display reduced eosinophil numbers in the blood as well as 
reduced IL-5 levels in the serum as compared to WT mice. WT and LXRα-/-β-/- mice were 
sensitized against OVA together with alum via the i.p. route and then challenged with 2 to 8 
consecutive OVA aerosols. (A) Blood was taken 24 h after the indicated OVA aerosol. Eosinophil 
numbers were determined by flow cytometry. (B) Protein levels of IL-5 and IL-3 were measured in the 
serum by luminex analysis. Data are shown as mean ± SD, n = 5 mice per group. The results show one 
representative experiment out of two independent experiments. Statistical analysis between two groups 
was performed using a Mann-Whitney test. Significant p-values were ranked as p < 0,05 (*), p < 0,01 
(**), and p < 0,001 (***). 
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Figure 5 | LXRα-/-β-/- chimeric mice display the same reduction in airway inflammation and IL-5 
serum levels seen in LXRα-/-β-/- mice. (A) Bone marrow chimeric mice were made by sublethally 
irradiating WT mice and reconstituting them with bone marrow (BM) from either WT or LXRα-/-β-/-
mice. Chimeric mice and regular WT control mice were sensitized against OVA together with alum 
via the i.p. route and then challenged with 6 consecutive OVA aerosols. (B) BAL was performed 24 h 
after the sixth OVA aerosol followed by flow cytometry-based differential cell counting. (C) After the 
second OVA aerosol, blood was taken by bleeding of the tail vein and protein levels of IL-5 were 
measured in the serum by luminex analysis. Data are shown as mean ± SD, n = 8 to 9 mice per group. 
The results show one representative experiment out of two independent experiments. Statistical 
analysis between two groups was performed using a Mann-Whitney test. Significant p-values were 
ranked as p < 0,05 (*), p < 0,01 (**), and p < 0,001 (***). 
 
Leukocytes are involved in mediating the regulatory role of LXR in eosinophilic asthma 
 
Asthma pathogenesis develops from an interplay between leukocytes and non-haematopoietic 
cells like airway epithelium and airway smooth muscle cells. To elucidate the role of 
haematopoietic cells versus non-haematopoietic cells, bone marrow transplantations were 
used to selectively eliminate LXR activity in bone marrow-derived cells. We generated bone 
marrow chimeric mice by sublethally irradiating WT mice and reconstituting them with bone 
marrow derived from LXRα-/-β-/- donor mice. As a control, we also reconstituted irradiated 
WT mice with WT bone marrow and included WT mice that had not been subjected to 
irradiation or bone marrow reconstitution (Fig. 5A). After 12 weeks, the mice were sensitized 
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to OVA and subjected to six consecutive OVA aerosols on a daily basis. WT recipients 
reconstituted with LXRα-/-β-/- bone marrow displayed reduced eosinophil numbers in the BAL 
as compared to WT recipients reconstituted with WT bone marrow (Fig. 5B). This reduction 
is similar to the one seen for LXRα-/-β-/-mice (Fig. 1B). In agreement with reduced 
eosinophilic airway inflammation, the protein levels of IL-5 in the serum after the second 
OVA aerosol challenge were also reduced in the WT recipients reconstituted with LXRα-/-β-/- 
bone marrow as compared to those reconstituted with WT bone marrow (Fig. 5C). This 
reduction in IL-5 levels in the serum is similar to the one seen in LXRα-/-β-/- mice (Fig. 4B). 
No difference in airway inflammation or serum IL-5 levels were observed between regular 
WT mice and WT recipients transplanted with WT bone marrow, indicating that the bone 
marrow transplantation had successfully reconstituted the haematopoietic system. 
 
 
1.4 Discussion 
 
In this study, we verified to what extent LXR activity contributes to the development of 
eosinophilic asthma in mice. To this end, we used mice deficient for either LXRα or LXRβ or 
for both isoforms. Loss of both isoforms resulted in reduced airway inflammation, airway 
elastic resistance and goblet cell hyperplasia. The attenuated airway inflammation seen for 
LXRαβ deficient mice was lost with single deficiencies, indicative of a functional redundancy 
for the LXR isoforms. In addition, we identified hematopoietic cells as the major determinant 
of the reduced airway inflammation associated with loss of LXR activity as evidenced by the 
use of bone marrow transplant studies. 
Previous reports have documented a negative role for LXR in IgE production17,20. The asthma 
mouse model used in this study is IgE-dependent and therefore we looked at IgE titers after 
allergen sensitization and after subsequent allergen challenges. We showed that allergen-
specific IgE serum levels were unchanged between allergen sensitized WT and LXRα-/-β-/- 
mice and were slightly increased in LXRα-/-β-/- mice after multiple OVA aerosol challenges. 
This implies a negative regulatory role for LXR in IgE production, consistent with current 
literature, and indicates that decreased airway inflammation associated with LXR deficiency 
was not caused by reduced allergen sensitization.  
Instead our results indicate that reduced airway inflammation upon loss of LXR activity is 
associated with attenuated type 2 cytokine expression. Whereas the nature of the T helper cell 
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response was not affected, CD4+ T cells in the lungs of LXR deficient mice were reduced in 
number and expressed lower levels of Th2 cytokines, such as IL-4, IL-5 and IL-13. In 
addition to reduced mRNA levels in CD4+ T cells, the protein levels of IL-5 and IL-13 were 
strongly reduced in the BALF of mice deficient for LXRα and LXRβ, supporting a role for 
LXR in eosinophilic asthma through positive regulation of type 2 cytokine expression. 
Along with a reduction in eosinophil numbers in the lungs, LXRα-/-β-/- mice also displayed 
reduced eosinophils in the blood together with strongly reduced IL-5 protein levels in the 
serum. Considering that IL-5 is the main effector cytokine driving eosinophil development in 
the bone marrow during eosinophilic inflammation23–28, we speculate that LXR regulates 
eosinophil development in the bone marrow during eosinophilic asthma by promoting IL-5 
expression. This is further supported by a recent study that identified IL-5 as a direct target 
gene of LXR transactivation29. 
Overall, our results show that attenuated eosinophilic inflammation, seen upon loss of LXR 
activity, is associated with decreased leukocyte expression of type 2 cytokines. This implies 
that, contrary to repression of pro-inflammatory cytokines driving Th1 and Th17 responses 
expression, LXR activity supports the expression of type 2 cytokines. 
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1.5 Material and Methods 
 
Mice 
 
C57BL/6Bom LXRα–/–, LXRβ–/– and LXRα-/-β-/- mice were generated as previously 
described30 and were bred in the animal facilities of the University of Ghent. Age- and sex-
matched 8-12 week old mice were used for all experiments. Mice were housed in specific 
pathogen-free condition in individually ventilated cages in a controlled day-night cycle and 
given food and water ad libitum. All experiments were approved by the animal ethics 
committee of Ghent University, in accordance with European guidelines. 
 
OVA/alum model of eosinophilic asthma 
 
Mice were sensitized to ovalbumin (OVA grade V, Sigma-Aldrich) by i.p. injection of 100 µg 
OVA adsorbed on 1 mg aluminium hydroxide (alum) (Sigma-Aldrich) in 0,5 ml endotoxin-
free PBS on days 0, 7 and 14. Starting from day 28, mice were challenged for 30 min with an 
aerosolized solution of 1% OVA (grade III, Sigma-Aldrich) in endotoxin-free PBS for 2 to 8 
consecutive days. Twenty-four hours after the indicated OVA aerosol mice were euthanized 
by i.p. injection of Nembutal (Medini NV). Blood was collected by bleeding of the orbital 
sinus and captured in an EDTA coated eppendorf for differential cell counting and in a regular 
eppendorf for serum preparation after overnight clotting at 4°C. Bronchoalveolar lavage 
(BAL) was performed with 4 x 1ml Hank’s balanced salt solution (Life Technologies) 
supplemented with 0,05 mM EDTA. Supernatant from the first 0,5 ml BALF was used for 
cytokine analysis. After BAL, lungs were isolated for CD4+ T cell isolation. Bone marrow 
was isolated from the tibia and the femur from one of the hind legs. 
 
Flow-cytometry based differential cell counting in BAL and blood 
 
Red blood cells were lysed with ACK lysis buffer (BioWhittaker) and cells were passed 
through a 70 µm cell strainer to remove any debris. To allow for differential cell counting, 
cells were labelled for the surface markers CD45 (30-F11), CD3 (145-2C11), SiglecF 
(RP/14), CD11c (HL3), CD4 (RM4-5), Ly6G (1A8) (BD Biosciences), CD8 (53-6.7), CD11b 
(M1/70), F4/80 (BM8) (eBiosciences) and CCR3 (83101) (R&D Systems) together with a 
live/dead marker (eBiosciences). Cells were labelled at 4°C in the presence of anti-
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CD16/CD32 (BD Biosciences) to block non-specific binding.. Measurements were performed 
either on a LSRII flow cytometer or a FACSVerse flow cytometer (BD Biosciences) and 
analysis was performed either with BD FACS Diva software or FlowJo software. The criteria 
that were used to distinguish the different cell types are shown in Fig. S1 and Fig. S2 
 
Measurement of airway hyper-reactivity 
 
For invasive measurement of dynamic elastance, mice were anesthetized with urethane, 
tracheotomized, and intubated with an 18G catheter. Natural breathing was stopped using d-
tubocurarine, followed by mechanical ventilation with a Flexivent apparatus (SCIREQ). 
Respiratory frequency was set at 120 breaths/min with a tidal volume of 0.2 ml and a positive-
end expiratory pressure of 2 ml H2O was applied. Increasing concentrations of metacholine 
(0–800 μg/kg) were administered via the jugular vein. Dynamic elastance was recorded after a 
standardized inhalation manoeuvre given every 10 s for 2 min. Baseline resistance was 
restored before administering the subsequent doses of metacholine. 
 
Histological analysis 
 
Lungs were fixed with 4% paraformaldehyde, embedded in paraffin, cut into 5 μm sections 
and stained with Periodic acid–Schiff (PAS) (Sigma Aldrich) to identify mucus-containing 
cells. The numerical scores for the abundance of PAS-positive mucus-containing cells in each 
bronchus were determined as follows: 0, less than 5% PAS-positive cells; 1, 5–25%; 2, 25–
50%; 3, 50–75%; 4, >75% as described by Tanaka et al.31. 
 
Gene expression in lung CD4+ T cells 
 
CD4+ T cells were isolated from homogenized lung tissue samples. Lung tissue was pooled 
per group and single cell suspensions were prepared by digestion of minced tissue with 1 
mg/ml collagenase type IV (Sigma-Aldrich) and 150 U/ml DNaseI (Roche) for 30 min at 37°. 
The digest was passed through a 70 μm cell strainer, and red blood cells were lysed with ACK 
lysis buffer. The CD4+ cell fraction was isolated through magnetic cell sorting with CD4 
(L3T4) MicroBeads (Miltenyi Biotec) according to the manufacturer’s instructions. Purity of 
the sample was checked with a flow cytometer and was 90-98%. Total RNA was prepared 
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with the RNeasy Mini Kit (Qiagen) and complementary DNA was prepared with Superscript 
II (Invitrogen). Quantitative-PCR (qPCR) was performed with the SYBRGreen mix (GC 
Biotech) on the Roche LightCycler 480 system (Applied Biosystems). Expression data was 
normalized to the expression levels of housekeeping genes. 
 
Measurement of cytokine levels in BALF and serum 
 
Cytokines were captured with luminex beads (Bio-Rad) and the cytokine levels were 
measured on a Luminex Bioplex suspension array system (Bio-Rad) according to the 
manufacturer’s instructions. 
 
Measurement of OVA-specific serum IgE levels 
 
OVA-specific IgE levels in the serum were determined by ELISA. Briefly, plates were coated 
with OVA (grade V, Sigma-Aldrich) and incubated with a 4-fold serial dilution of the serum 
samples. The OVA-bound IgE antibodies were detected with a HRP-conjugated rat anti-
mouse IgE detection antibody (Southern Biotec). The plate was developed with TMB 
substrate (BD OptEIA) and measurements were made at 450/655nm using a microplate reader 
after stopping the reaction with sulphuric acid.  
 
Generation of bone marrow chimeras 
 
Mice were sublethally irradiated (10 Gy) and after 24 h the bone marrow was reconstituted by 
i.v. injection of 10 million fresh bone marrow cells from WT or LXRα-/-β-/- mice. To protect 
the mice from infection, they received 0,2 % of the antibiotic neomycin sulphate (Sigma-
Aldrich) in their drinking water until 3 to 4 weeks after irradiation. Mice were used in 
experiments 8 to 12 weeks after bone marrow reconstitution. 
 
Statistics 
 
Data are shown as mean ± SD. Statistical analysis between two groups was performed using a 
Mann-Whitney test. Differences in airway elastance to metacholine was analysed by two-way 
ANOVA with repeated-measures. Significant p-values were ranked as p < 0,05 (*), p < 0,01 
(**), and p < 0,001 (***). 
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1.7 Supplementary Data 
 
 
Figure S1 | Mice deficient for a single LXR isoform display moderate to no reduction in airway 
inflammation in a Th2-driven asthma model as compared to WT mice. Cellular airway 
inflammation was assessed by flow cytometry-based differential cell counting on the BAL cells. (A) 
Singlet cells were gated based on forward and side scatter. T cells were gated as CD3+ autofluorescent- 
cells and further subdivided in CD4+ T cells and CD8+ T cells based on the respective surface markers. 
Subsequent NOT gates were used to identify alveolar macrophages (AM) which were gated as CD11c+ 
autofluorescent+ cells, eosinophils as SiglecF+ CCR3+ cells and neutrophils as CD11b+ Ly6G+. (B-C) 
WT, LXRα-/- and LXRβ-/- mice were sensitized against OVA together with alum via the i.p. route and 
then challenged with aerosolized OVA. Differential cell counts were measured in the BAL 24 h after 
the sixth OVA aerosol. Data are shown as mean ± SD, n = 5 to 7 mice per group. The results show one 
representative experiment out of two independent experiments. Statistical analysis between two groups 
was performed using a Mann-Whitney test. Significant p-values were ranked as p < 0,05 (*), p < 0,01 
(**), and p < 0,001 (***). 
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Figure S2 | Gating strategy eosinophils in blood. Singlet cells were gated based on forward and side 
scatter. Live leukocytes were gated as CD45+ live/dead- cells. Eosinophils were gated as SiglecF+ 
CCR3+ F4/80+ CD11b+ cells. 
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1.8 Additional Data 
 
Although LXR deficient mice represent a good tool to investigate the function of LXR, the 
use of LXR agonists is complementary to these studies and serves as strategy to increase LXR 
activity. Here, we treated mice with 50µg of the LXR agonist T0901317 by intraperitoneal 
injection, which resulted in a strong upregulation of LXR target genes in the liver and BAL 
(Fig. A1A). Mice were treated with the LXR agonist 2 hours before aerosol challenge with 
1% OVA, resulting in a modest increase in eosinophil numbers in the BAL after exposure to 
two to four OVA aerosol challenges. In contrast, LXR activation resulted in a slight decrease 
in eosinophil numbers after six to eight challenges (Fig. A1B). Due to high variability in the 
different treatment groups, none of the observed differences reached statistical significance 
and as thus no conclusions can be made from these experiments. 
 
Figure A1 | LXR agonist treatment of WT mice in a Th2-driven asthma model. WT mice were 
sensitized against OVA together with alum via the i.p. route and then were given an i.p. injection with 
50µg T0901317 or with 5% DMSO as a control 2h before challenge with aerosolized OVA. (A) 
mRNA levels of LXR target genes were measured in the liver and BAL 6h after a single T0901317 
injection. Samples were pooled per group and analysed in triplicate. (B) Eosinophils in the BAL were 
measured by flow cytometry 24 h after the indicated number of 1% OVA aerosols. Data are shown as 
mean ± SD, n = 5 mice per group. Statistical analysis between two groups was performed using a 
Mann-Whitney test. No significant differences were seen.  
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2.1 Introduction 
 
Eosinophils are granulocytes that develop in the bone marrow from pluripotent progenitors. 
After maturation, they are released in the blood and circulate through the body. In the blood 
eosinophils have a half-life of around 18 hours and constitute only a small fraction (less than 
5%) of the leukocytes. The majority of mature eosinophils reside in mucosal tissues such as 
the thymus, uterus, mammary glands and gastrointestinal tract. Recruitment into these tissues 
occurs in response to appropriate stimuli, most notably the cytokine IL-5 and the eotaxin 
chemokines. An increase in eosinophils in the blood, i.e. eosinophilia, is typically seen in 
patients with parasitic infection and in patients with allergic disease like asthma1.  
 
 
Figure 1 | Eosinophil development in mouse and human. Haematopoietic stem cells (HSC) in the 
bone marrow give rise to a common myeloid progenitor (CMP). Human eosinophil progenitors (eoP) 
arise directly from the common myeloid progenitor, whereas mouse eosinophil progenitors arise from 
the common myeloid progenitor via the granulocyte/monocyte progenitor (GMP) that also gives rise 
to neutrophils, basophils and monocytes. Adapted from2. 
 
In the bone marrow, eosinophils originate from haematopoietic stem cells (HSCs) under the 
influence of the combined activity of GM-CSF, IL-3 and IL-5. In mouse haematopoiesis, 
eosinophils develop as a distinct subpopulation downsteam of the granulocyte/monocyte 
progenitor (GMP) (Fig. 1). Lineage-committed eosinophil progenitor (eoP) cells are described 
as IL-5Rα+ Lin- Sca1- CD34+ cKitlow cells3. Expression of the IL-5Rα (CD125) occurs as the 
result of eosinophil lineage commitment. This implies that IL-5 signalling does not instruct 
lineage commitment but only supports proliferation and maturation of eosinophil progenitor 
cells after lineage commitment. In steady-state, bone marrow eosinophil progenitor cells 
represent only 0.05% of total cells, but this population can expand in response to helminth 
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infection3 and allergic asthma4. In human haematopoiesis, eosinophil lineage-committed 
progenitors (IL-5Rα+CD34+ CD38+ IL-3Rα+ CD45RA−) are direct descendants of the IL-5Rα− 
common myeloid progenitor (CMP) and constitute a lineage that is distinct from the 
granulocyte/monocyte progenitors (GMP), which gives rise to neutrophils and basophils in 
culture but not eosinophils (Fig. 1). In human bone marrow, the eosinophil progenitor cells 
represents 0.033% of mononuclear cells, a number that increases three- to fourfold in 
eosinophilia patients5. Although the eosinophil developmental pathways differ slightly 
between the human and the mouse, the use of key transcription factors is preserved between 
both species5. Eosinophil lineage commitment and differentiation is regulated by the interplay 
of a few key transcription factors, including GATA-binding protein family (GATA1 and 
GATA2), CCAAT/enhancer-binding proteins (such as C/EBPα and C/EBPε) and PU.12.  
Cholesterol homeostasis has recently been identified as an important factor in haematopoietic 
stem and progenitor cell (HSPC) proliferation. Mice displaying intracellular accumulation of 
cholesterol were shown to display HSPC hyperproliferation due to an increased 
responsiveness to IL-3 and GM-CSF signalling6,7. As liver X receptors (LXRs) are major 
regulators of cholesterol homeostasis and LXR deficiency results in intracellular cholesterol 
accumulation8, this led us to investigate the role of LXR in haematopoiesis and more notably 
in eosinopoiesis. 
 
2.2 Results 
 
LXR deficient mice display increased levels of eosinophil progenitor cells in the bone marrow  
 
To investigate the role of LXR in eosinopoiesis, we measured the number of eosinophil 
progenitor cells in the bone marrow of mice deficient for either LXRα, LXRβ or both (LXRα-
/-, LXRβ-/- or LXRα-/-β-/-) as compared to WT mice. The percentage of lineage-committed 
eosinophil progenitor (eoP) cells as well as the percentage of their ancestors, namely the 
granulocyte/monocyte progenitor (GMP) and the common myeloid progenitor (CMP) were 
measured in the bone marrow by flow cytometry-based cell counting (Fig. 2). The percentage 
of all three progenitor cell population was increased in the bone marrow of LXRα-/-β-/- mice 
as compared to WT mice (Fig. 3A). No significant differences were seen in the number of 
progenitor cells in the bone marrow of the single LXR knock-out mice, apart from a slight 
increase in GMPs in the LXRβ-/- mice (Fig. 3A). 
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Population  % of total bone marrow 
CMP Lin-Sca1-cKit+CD34+CD16/32low 0.440 ± 0.072 
GMP Lin-Sca1-cKit+CD34+CD16/32+ 0.450 ± 0.023 
eoP Lin-Sca1-cKitlowCD34+CD125+ 0.057 ± 0.027 
 
Figure 2 | Haematopoietic progenitor cells in mouse bone marrow. The number of haematopoietic 
progenitor cells as well as lineage-committed eosinophil progenitors in the bone marrow was 
determined by flow cytometry-based differential cell counting. Singlet cells were gated based on 
forward and side scatter. In the lineage- cell population, haematopoietic stem cells were defined as 
cKit+Sca1- and were further subdivided in CD16/CD32+CD34+ cells (GMP) and CD16/CD32-CD34+ 
cells (CMP). Lineage-committed eosinophil progenitor (eoP) cells were defined as CD34+Sca1-
CD125+cKitlow cells. 
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Figure 3 | Eosinophil progenitor cells in the bone marrow and mature eosinophils throughout 
the body of LXR deficient mice in steady-state. (A) The percentage of the eosinophil progenitor 
populations CMP, GMP and eoP were determined in the bone marrow of WT, LXRα-/-, LXRβ-/- and 
LXRα-/-β-/- mice. In addition to eosinophil progenitors, (B) also the number of mature eosinophils was 
measured in the blood, lungs and bone marrow of these mice. Data are shown as mean ± SD, n = 4 
mice per group. The results show one representative experiment out of three independent experiments. 
Statistical analysis between two groups was performed using a Mann-Whitney test. Significant p-
values were ranked as p < 0,05 (*), p < 0,01 (**) and p < 0,001 (***). 
 
To assess whether the increase in eosinophil progenitor cells influenced the level of mature 
eosinophils, the number of eosinophils was measured in the bone marrow and in the periphery 
of LXRα-/-, LXRβ-/- and LXRα-/-β-/- mice as compared to WT mice. In contrast to an increase 
in progenitor cells associated with LXRαβ deficiency, no difference was seen in the 
percentage of mature eosinophils in the blood, lungs and bone marrow (Fig. 3B). Apart from 
eosinophils, GMP cells can also give rise to monocytes and neutrophils9. In accordance to the 
normal levels of eosinophils, also no difference was seen for the number of monocytes and 
neutrophils in the blood of LXRα-/-β-/- mice as compared to WT mice (data not shown).  
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LXR deficient mice display increased levels of eosinophil progenitor cells in the bone marrow 
under conditions of eosinophilic inflammation 
 
Eosinophil production in the bone marrow is increased during eosinophilic asthma1,2,4. To 
assess whether the effect of LXR deficiency on eosinophil development was different during 
eosinophilia, we looked at the same eosinophil progenitor cell populations in mice subjected 
to an eosinophilic asthma model. In this model, mice were first sensitized to the model 
allergen ovalbumin (OVA) in the presence of aluminium hydroxide (alum) and were then 
exposed to six daily OVA aerosol challenges. An increase in percentage of all three 
progenitor populations was seen for LXRα-/-β-/- mice as compared to WT mice (Fig. 4) 
(kinetic in supplementary data Fig. S1), thus displaying a similar pattern as seen in the steady-
state condition (Fig. 3A). However, the increase in lineage-committed eosinophil progenitor 
cells is not confided to LXRα-/-β-/- mice and is also seen in mice only deficient for the LXRα 
isoform.  
 
 
 
 
 
Figure 4 | Eosinophil progenitor cells in the bone marrow of LXR deficient mice during 
eosinophilic asthma. WT, LXRα-/-, LXRβ-/- and LXRα-/-β-/- mice were sensitized against OVA 
together with alum via the i.p. route and then challenged with six daily OVA aerosols. The percentage 
of the eosinophil precursor populations CMP, GMP and eoP were determined in the bone marrow. 
Data are shown as mean ± SD, n = 6 mice per group. The results show one representative experiment 
out of three independent experiments. Statistical analysis between two groups was performed using a 
Mann-Whitney test. Significant p-values were ranked as p < 0,05 (*), p < 0,01 (**) and p < 0,001 
(***). 
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LXR deficient mice display reduced levels of mature eosinophils throughout the body under 
conditions of eosinophilic inflammation 
 
To investigate whether the increased percentage of eosinophil progenitors in the bone marrow 
during eosinophilic asthma had an impact on mature eosinophil numbers, we assessed the 
number of eosinophils in the blood, bronchoalveolar lavage (BAL) and bone marrow of 
allergen-sensitized LXRα-/-β-/- mice after six daily OVA aerosol challenges as compared to 
WT mice. LXR deficient mice displayed a reduced percentage of eosinophils in the blood and 
bone marrow (Fig. 5A) as well as reduced eosinophil numbers in the BAL (Fig. 5B). As 
eosinophils develop from eosinophil progenitors in the bone marrow under the influence of 
GM-CSF, IL-3 and IL-5, we measured the protein levels of these cytokines in the serum after 
two OVA aerosol challenges. The protein level of IL-5 was significantly reduced in the serum 
of LXRα-/-β-/- mice as compared to WT mice (Fig. 5C), while GM-CSF and IL-3 were not 
detectable. 
 
Figure 5 | Mature eosinophils throughout the body of LXR deficient mice during eosinophilic 
asthma. WT and LXRα-/-β-/- mice were sensitized against OVA together with alum via the i.p. route 
and then challenged with six daily OVA aerosols. The number of mature eosinophils was measured in 
the (A) blood, bone marrow and (B) bronchoalveolar lavage (BAL). (C) After two OVA aerosol 
challenges blood was taken by bleeding of the tail vein and the protein level of IL-5 was measured in 
the serum by luminex analysis. Data are shown as mean ± SD, n = 6 mice per group. The results show 
one representative experiment out of three independent experiments. Statistical analysis between two 
groups was performed using a Mann-Whitney test. Significant p-values were ranked as p < 0,05 (*), p 
< 0,01 (**) and p < 0,001 (***). 
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2.3 Discussion 
 
Eosinophils develop from lineage-committed eosinophil progenitor cells in the bone marrow 
that develop downstream of the granulocyte/monocyte progenitor (GMP) and the common 
myeloid progenitor (CMP). Eosinophil lineage commitment and maturation are controlled by 
a network of transcription factors (GATA-1, PU.1 and c/EBPs) and growth factors (IL-5, 
GM-CSF and IL-3). After maturation, the eosinophils leave the bone marrow and circulate in 
the blood throughout the body.  
In this study, we investigated the role of the liver X receptor (LXR) in eosinophil 
development by measuring the number of eosinophil progenitor cells in the bone marrow as 
well as the number of mature eosinophils in the periphery of LXR deficient mice. Mice 
deficient for both LXRα and LXRβ displayed a significantly increased percentage of lineage-
committed eosinophil progenitor cells as well as GMP and CMP cells. Increased numbers of 
haematopoietic stem and progenitor cells (HSPCs) have already been described in mice 
displaying intracellular accumulation of cholesterol, resulting from a deficiency in the 
cholesterol transporters ABCA1 and ABCG17. ABCA1-/-ABCG1-/- mice showed an increased 
number of GMP and CMP cells in the bone marrow, which resulted in an elevated number of 
fully differentiated neutrophils, eosinophils and monocytes in the bone marrow and blood7. 
Similar results were obtained in mice deficient for the cholesterol carrier protein apoE6. 
Cholesterol is secreted from HSPCs through ABCA1 and ABCG1 and loaded onto apoE, 
promoting cholesterol efflux. When HSPCs lack either apoE or ABCA1 and ABCG1, the 
cholesterol efflux pathway is disrupted and cholesterol accumulates in the cell. Reportedly, 
intracellular cholesterol accumulation in HSPCs makes the cells more responsive to IL-3 and 
GM-CSF, resulting in increased HSPC proliferation6,7. LXRs are major regulators of 
cholesterol homeostasis through regulation of the expression of genes involved in cholesterol 
trafficking such as ABCA1, ABCG1 and apoE10. Activation of LXR by oxysterols results in 
increased cholesterol efflux and LXR deficiency is associated with intracellular cholesterol 
accumulation8. In line herewith, we now show that LXR deficiency is associated with 
increased numbers of lineage-committed eosinophil progenitors, GMPs and CMPs. However, 
in contrast to ABCA1 and ABCG1 deficiency, LXR deficient mice did not display 
neutrophilia, eosinophilia or monocytosis, suggesting that the mechanism through which LXR 
mediates HSPC expansion might differ from the one described for ABCA1 and ABCG17. 
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An alternative or complementary explanation might be that after eosinophil lineage-
commitment the progenitor cells fail to differentiate into mature eosinophils, resulting in 
progenitor accumulation. Eosinophil lineage commitment and maturation is controlled by the 
collaborative actions of key transcription factors including, C/EBPs, GATA-1 and PU.12,9. 
The myeloid transcription factor PU.1 poses as a potential candidate for mediating LXR-
dependent regulation of eosinophil development as is evidenced by their documented cross-
talk. A role for PU.1 in LXR target gene expression has been described by two separate 
cistrome analyses on macrophage cell lines11,12. The study by Heinz et al. revealed that a large 
proportion of LXRβ binding sites are within 100bp of PU.1 binding elements, and that their 
occupancy requires PU.1, which was shown to prime binding of LXR to the DNA by 
promoting H3K4 monomethylation of the genomic region, resulting in an open chromatin 
structure11. Whereas this study describes PU.1-dependent regulation of LXR target genes, 
another report has revealed a role for LXRα in promoting PU.1-dependent gene expression13. 
Here, LXRα was shown to activate IRF8 gene expression in macrophages, which resulted in 
enhanced IRF8/PU.1 binding to the promoter of the Arg1 gene and increased expression13. 
In a second approach, we addressed the number of lineage-committed eosinophil progenitor 
cells in a pathological condition displaying eosinophilia, namely eosinophilic asthma. In 
accordance to steady-state condition, LXR deficient mice displayed an expansion of lineage-
committed eosinophil progenitor, GMP and CMP cells during eosinophilic asthma as 
compared to WT mice. Strikingly, the increase in eosinophil progenitor cells in the bone 
marrow of LXR deficient was not reflected at the level of mature eosinophils, which were 
reduced in the blood, lung and bone marrow. The reduction in mature eosinophils was 
associated with reduced IL-5 levels in the serum of LXRα-/-β-/- mice and points towards a 
defect in eosinophil maturation. While under steady-state conditions IL-5 is shown to be 
dispensable for eosinophil development, it is critical under conditions of eosinophilia and 
represents the major maturation factor for eosinophils after lineage commitment12–16. As 
IL-5 has also already been identified as a direct target gene of LXR transactivation19, we 
speculate that LXR regulates eosinophil maturation from lineage-committed progenitor cells 
in the bone marrow during eosinophilic asthma by promoting IL-5 expression.  
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Together, our data shows that LXR deficiency is associated with an expansion of lineage-
committed eosinophil progenitor cells in the bone marrow, without affecting the level of 
mature eosinophils in the periphery. Under conditions of eosinophilic inflammation, LXRα-/-
β-/- mice also displayed an increase in eosinophil progenitors in the bone marrow, while 
showing a reduction in mature eosinophils in the lungs, blood and bone marrow. The latter 
identifies LXR as a positive regulator of eosinophil maturation under conditions of 
eosinophilia, potentially through regulation of IL-5 expression. 
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2.4 Material and Methods 
 
Mice 
C57BL/6Bom LXRα–/–, LXRβ–/– and LXRα-/-β-/- mice were generated as previously 
described20 and were bred in the animal facilities of the University of Ghent. Age- and sex-
matched 8-12 week old mice were used for all experiments. Mice were housed in specific 
pathogen-free condition in individually ventilated cages in a controlled day-night cycle and 
given food and water ad libitum. All experiments were approved by the animal ethics 
committee of Ghent University, in accordance with European guidelines. 
 
OVA/alum model of eosinophilic asthma 
Mice were sensitized to ovalbumin (OVA grade V, Sigma-Aldrich) by i.p. injection of 100 µg 
OVA adsorbed on 1 mg aluminium hydroxide (alum) (Sigma-Aldrich) in 0,5 ml endotoxin-
free PBS on days 0, 7 and 14. Starting from day 28, mice were challenged for 30 min with an 
aerosolized solution of 1% OVA (grade III, Sigma-Aldrich) in endotoxin-free PBS for six 
consecutive days.  
 
Isolation and single cell preparation of BAL, lung, blood and bone marrow 
Mice were euthanized by i.p. injection of Nembutal (Medini NV). Blood was collected by 
bleeding of the orbital sinus and captured in an EDTA coated eppendorf for differential cell 
counting and in a regular eppendorf for serum preparation after overnight clotting at 4°C. 
Either bronchoalveolar lavage (BAL) was performed with 4 x 1 ml Hank’s balanced salt 
solution (Life Technologies) supplemented with 0,05 mM EDTA or the lungs were isolated. 
A single cell suspension of lung tissue was prepared by digestion of minced tissue with 1 
mg/ml collagenase type IV (Sigma-Aldrich) and 150 U/ml DNaseI (Roche) for 30 min at 
37°C, after which the digest was passed through a 70 μm cell strainer. Bone marrow was 
isolated from the tibia and the femur from one of the hind legs. Red blood cells were lysed 
with ACK lysis buffer (BioWhittaker) and cells were passed through a 70 µm cell strainer to 
remove any debris.  
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Flow-cytometry based differential cell counting of mature eosinophils and eosinophil 
progenitors 
For differential cell counting of mature eosinophils, cells were labelled for the surface 
markers CD45 (30-F11), SiglecF (RP/14) (both from BD Biosciences), CD11b (M1/70), 
F4/80 (BM8) (both from eBiosciences) and CCR3 (83101) (R&D Systems) together with a 
live/dead marker (eBiosciences). Cells were labelled at 4°C in the presence of anti-
CD16/CD32 (BD Biosciences) to block non-specific binding. For differential cell counting of 
haematopoietic progenitors, cells were labelled with a coctail of lineage-associated markers 
(eBiosciences) and for the surface markers CD34 (RAM34), CD125 (T21), CD16/CD32 
(2.4G2), Sca1 (D7) (all from BD Biosciences) and cKit (ACK2) (eBiosciences). 
Measurements were performed on a FACSVerse flow cytometer (BD Biosciences) and 
analysis was performed either with BD FACS Diva software or FlowJo software. 
 
Measurement of cytokine levels in serum 
Cytokines were captured with luminex beads (Bio-Rad) and the cytokine levels were 
measured on a Luminex Bioplex suspension array system (Bio-Rad) according to the 
manufacturer’s instructions. 
 
Statistics 
Data are shown as mean ± SD. Statistical analysis between two groups was performed using a 
Mann-Whitney test. Significant p-values were ranked as p < 0,05 (*), p < 0,01 (**), and p < 
0,001 (***). 
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2.6 Supplementary Data 
 
 
 
Figure S1 | Eosinophil progenitor cell kinetic in the bone marrow of LXR deficient mice 
throughout the asthma response. WT and LXRα-/-β-/- mice were sensitized against OVA together 
with alum via the i.p. route and then challenged with two to eight daily OVA aerosols. The percentage 
of the eosinophil progenitor populations (A) eoP, (B) GMP and (C) CMP were determined in the bone 
marrow. Data are shown as mean ± SD, n = 5 mice per group. The results show one representative 
experiment out of two independent experiments. Statistical analysis between two groups was 
performed using a Mann-Whitney test. Significant p-values were ranked as p < 0,05 (*), p < 0,01 (**) 
and p < 0,001 (***). 
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1.1 Abstract 
 
The immunostimulatory activity of mycobacterial cell wall lipids is well known and has been 
exploited in a variety of Th1-inducing adjuvant formulations; however, the associated toxicity 
has hampered their use in human vaccines. Here, we addressed the adjuvant potential of the 
mycobacterial cell wall component, mycolic acid (MA), which shows a milder pathological 
profile as compared to complex mycobacterial preparations. Mycolic acids are present in the 
cell wall of Mycobacterium tuberculosis as a complex mixture of molecules with a common 
general structure but with variable functional groups in the meromycolate chain. In this study 
we addressed the relationship between the molecular structure of the mycolic acids and their 
contribution to the development of T cell-mediated immune responses using single synthetic 
mycolic acids, differing in oxygenation class and cis versus trans proximal cyclopropane 
configuration. We showed that subcutaneous delivery of individual liposome-formulated 
mycolic acids elicited distinct antigen-specific Th1 and cytotoxic T cell immune responses 
dependent on the molecular structure. The most prominent Th1 and cytotoxic T cell response 
was seen in mice immunized with cis αMA and cis kMA and was comparable to that seen 
with AddaVax immunization. Furthermore, we showed that intratracheal immunization with 
cis mMA and cis kMA, both oxygenated mycolic acids with a proximal cis cyclopropane, 
elicited a strong Th17 response in the lungs. The immunomodulatory activities of the variant 
mycolic acids could be attributed to the presence and the nature of the functional groups in the 
meromycolate chain, a feature that is characteristic of pathogenic mycobacteria. In summary, 
these data show that the use of select synthetic mycolic acids represent a promising new 
strategy for the development of a vaccine adjuvant conferring either Th1 and cytotoxic T cell-
mediated immunity after subcutaneous delivery or Th17-mediated immunity after pulmonary 
delivery. 

 135 | P a g e  
 
1.2 Introduction 
 
Vaccine adjuvants are commonly used to enhance the immune response to an antigen and to 
influence the nature of the elicited immune response, either conferring antibody-mediated or 
T cell-mediated immunity. Commonly used adjuvants in human vaccines such as aluminium 
hydroxide and oil-in-water emulsions induce antibody production but do not induce strong T 
cell-mediated immune responses. This makes these adjuvants inadequate for combating 
pathogens that require the induction of a strong Th1 and cytotoxic T cell immune response 
such as Mycobacterium tuberculosis, Leishmania and Human Immunodeficiency Virus1. 
Adjuvants based on water-in-oil emulsions with heat-killed M. tuberculosis as main 
component, typically Complete Freund’s Adjuvant (CFA), are highly efficient in inducing 
strong T cell-mediated immunity. However because of their high toxicity, much of these 
adjuvants are not suited for use in humans. The mycobacterial cell wall component, mycolic 
acid, was also shown to elicit host cell innate immune activation in the lungs and displays a 
mild pathological profile making them potentially suited for use as vaccine adjuvant2–4.  
Mycolic acids are highly hydrophobic long-chain α-alkyl β-hydroxy fatty acids present in the 
outer membrane of Corynebacterineae, a distinct group of bacteria including the lung 
pathogen M. tuberculosis. Natural mycolic acids are present in the bacterial cell membrane 
either as membrane bound penta-arabinose tetramycolates or as non-covalently bound 
mycolate esters such as trehalose dimycolate (TDM, cord factor). The mycolic acids 
synthesized by M. tuberculosis present a complex mixture of molecules with a common 
general structure but with a large variability in chain lengths and functional groups. While the 
shorter α-alkyl mycolic acid chain, i.e. the corynomycolate chain, does not contain any 
functional groups, the longer β-hydroxy mycolic acid chain, i.e. the meromycolate chain, 
contains two functional groups. Based on the distal functional group, three major mycolic acid 
classes can be distinguished, namely α-mycolic acids (αMAs), methoxy-mycolic acids 
(mMAs) and keto-mycolic acids (kMAs). The proximal functional group consist mainly of a 
cyclopropane that can either have a cis or trans configuration in the oxygenated keto- and 
methoxy-MAs and almost exclusively occurs in the cis configuration in αMAs5,6. In a 
previous report by Vander Beken et al., we showed that the functional groups and their 
respective stereochemistry have a great impact on the inflammatory activity of the mycolic 
acid compounds in the lungs, ranging from pro- to anti-inflammatory4. While mycolic acids 
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were shown to modulate innate immunity, the contribution of mycolic acid to the 
development of adaptive immunity towards M. tuberculosis has not yet been investigated.  
In this study we addressed the potential use of single synthetic mycolic acids, varying in 
oxygenation class and cis versus trans proximal cyclopropane configuration, as vaccine 
adjuvant for induction of a strong T cell immune response. We identify mycolic acids as 
important immunomodulators in the development of systemic Th1 and cytotoxic T cell-
mediated immunity after subcutaneous delivery and local Th17-mediated immunity after 
pulmonary delivery, features that are dependent on the presence and on the nature of the 
functional groups in the meromycolate chain.  
 
1.3 Results 
 
Synthetic mycolic acids are formulated in phosphatidyl choline liposomes for in vivo delivery 
In this study we addressed the immunomodulatory properties of single synthetic mycolic acid 
isomers, representing all three naturally occurring mycolic acid classes, varying in cis versus 
trans cyclopropane configuration (Fig. 1). The αMA contains two cyclopropane rings in cis 
configuration (cis αMA). The methoxy-MA has a distal (S,S)-α-methyl-methoxy group and a 
proximal cyclopropane group that occurs either in cis or trans configuration (cis and trans 
mMA). The keto-MA either consists of a distal (S)-α-methyl-ketone group and of a proximal 
cis-cyclopropane (cis kMA) or of a mixture of both epimers of the distal α-methyl-ketone 
group with S- and R-stereochemistry and of a proximal trans-cyclopropane (trans kMA epi). 
An additional synthetic molecule, the MA-backbone (bbMA), consisting of a mixture of four 
stereoisomers of the MA-motif with a short meromycolic chain free of functional groups, was 
included as a control for the presence of the functional groups in the meromycolate chain.  
As MAs are highly hydrophobic and are not soluble in aqueous solutions they were 
formulated into phosphatidyl choline liposomes together with the antigen protein ovalbumin 
(OVA). The adjuvant potency of liposome-formulated MAs together with OVA was 
compared to liposome-formulated OVA and OVA dissolved as such in PBS. The different 
MAs were set against AddaVax, a squalene-based oil-in-water emulsion based on the 
formulation of MF59 which is currently used as adjuvant in multiple influenza vaccines in 
Europe1. 
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Figure 1 | Chemical structure of synthetic mycolic acids. The general structure of a mycolic acid 
consists of a mycolic motif that contains a corynomycolate chain without functional groups and of a 
meromycolate chain with two functional groups. The proximal and distal functional group of the 
meromycolate chain is depicted for all compounds with its stereochemistry. In the nomenclature cis or 
trans refers to the stereochemistry of the proximal cyclopropane group. αMA, mMA and kMA 
represent mycolic acids with a distal functional group consisting of a cyclopropane, a methoxy or a 
ketone group respectively. The length of the carbon chains is represented by a, b, c, d. The mycolic 
acid backbone (bbMA) represents a mixture of four stereoisomers of the mycolic motif with a short 
meromycolic chain without functional groups. 
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Subcutaneous immunization 
In a first instance, the variant antigen formulations were delivered by the subcutaneous route. 
Either we performed a single immunization or a classical prime-boost vaccination strategy 
consisting of two immunizations with a 3-week interval (Fig. 2A). One week after the last 
immunization, we measured the number of OVA-specific IFNγ-producing CD8+ T cells in the 
spleen by ELISPOT analysis. Immunization with cis αMA resulted in a modest CD8+ IFNγ 
response in the spleen already one week after a single immunization as compared to liposomal 
formulation of OVA alone or together with bbMA (Fig. 2B). No CD8+ T cell response was 
seen in splenocytes of mice one week after immunization with AddaVax (Fig. 2B). 
Administration of a second immunization, thus applying a conventional prime-boost schedule, 
strongly increased the number of IFNγ-producing CD8+ T cells in splenocyte culture from 
mice. When mice were immunized with liposome-formulated MAs an increased number of 
IFNγ-producing CD8+ T cells were apparent for cis αMA and cis kMA and this was similar to 
the number of IFNγ-producing CD8+ T cells observed one week after prime-boost 
immunization with AddaVax (Fig. 2C). For cis kMA immunization, an IFNγ response was 
also observed in the splenocyte culture in absence of OVA peptide restimulation (Fig. 2C). 
In addition to CD8+ cytotoxic T cells, also the number of IFNγ-producing CD4+ T cells was 
measured by ELISPOT analysis after immunization with the different antigen formulations. 
One week after a single immunization a moderate CD4+ IFNγ response is seen in the spleen 
of mice immunized with cis αMA and no CD4+ IFNγ response is seen for any of the other MA 
formulations or for AddaVax immunization (Fig. 3A). One week after a second immunization, 
the number of IFNγ-producing CD4+ T cells was highly increased in mice immunized with cis 
kMA and displayed a 3-fold increased response as compared to AddaVax immunization, 
whereas the IFNγ response in cis αMA-immunized mice was not further increased (Fig. 3B). 
Immunization with cis mMA, trans mMA and trans kMA epi resulted in a more moderate 
CD4+ IFNγ response similar to AddaVax immunization (Fig. 3B). Production of IFNγ by 
CD4+ T cells was also assessed by luminex analysis of the supernatans after splenocyte 
stimulation with OVA peptide for 48h. Production of IFNγ by CD4+ T cells was induced after 
immunization by all MAs compounds except for trans kMA epi and was similar to IFNγ 
production by splenocytes of AddaVax immunized mice (Fig. 3C).  
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Figure 2 | Antigen-specific IFNγ-producing CD8+ T cells in the spleen after subcutaneous 
mycolic acid immunization. (A) Mice were immunized s.c. at day 0 with PBS, OVA alone or with 
OVA in emulsion with AddaVax or formulated in liposomes with or without mycolic acids. The 
number of IFNγ-producing cells in the spleen was measured (B) at day 7 and (C) at day 28 by 
ELISPOT analysis after splenocyte stimulation with no peptide or MHCI-restricted OVA(257-264) 
peptide. These results show one representative experiment out of two independent experiments. 
Spleens were pooled per group of 5 mice and analysed in quadruplicate. Data are mean ±SD. 
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Figure 3 | Antigen-specific IFNγ-producing CD4+ T cells in the spleen after subcutaneous 
mycolic acid immunization. Mice were immunized s.c. at day 0 with PBS, OVA alone or with OVA 
in emulsion with AddaVax or formulated in liposomes with or without mycolic acids. The number of 
IFNγ-producing cells in the spleen was measured (A) at day 7 and (B) at day 28 by ELISPOT analysis 
after splenocyte stimulation with no peptide or MHCII-restricted OVA(323-339) peptide. (C) At day 
28, IFNγ protein levels in the supernatans were measured by luminex analysis. These results show one 
representative experiment out of two independent experiments. Spleens were pooled per group of 5 
mice and analysed in quadruplicate. Data are mean ±SD.  
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In order to investigate the B cell immune response elicited by MA vaccination, OVA-specific 
antibody titers in the serum were determined by ELISA as well as the numbers of activated B 
cells in the draining lymph nodes by flow cytometry-based cell counting (Fig. S1). One week 
after prime-boost subcutaneous immunization, mice immunized with cis αMA and cis kMA, 
showed a weak OVA-specific IgG1 response as compared to AddaVax immunization, whereas 
immunization with the other MA formulations resulted in a reduced antibody response as 
compared to liposomal formulation of OVA alone (Fig. 4A). Immunization with none of the 
MA formulations resulted in an OVA-specific IgG2c response, while AddaVax immunization 
induced a strong OVA-specific IgG2c antibody response (Fig. 4B). The absence of OVA-
specific antibodies in the serum of mice immunized with the variant MAs is in sharp contrast 
with the high number of activated B cells observed in the inguinal lymph nodes after 
immunization with cis αMA, trans mMA and cis kMA, which were similar or higher as seen 
after AddaVax immunization (Fig. 4C).  
 
 
 
Intratracheal immunization 
 
Several studies have shown that mucosal vaccination with Bacillus Calmette-Guérin (BCG) 
mediates superior protection against M. tuberculosis when compared to parenteral vaccination 
routes7–9. In addition, mucosal vaccination is reported to confer protection against M. 
tuberculosis infection by inducing a strong Th17 immune response in the lungs10. Therefore, 
we tested whether intratracheal (i.t.) immunization with the variant MA formulations could 
induce a Th1/Th17 immune response in the lungs. As AddaVax is only suited for parenteral 
vaccine delivery, it was not included in this experiment. One week after i.t. prime-boost 
immunization, the number of IFNγ- and IL-17-producing CD4+ T cells in the lungs was 
measured by flow cytometry-based cell counting. A modest increase in the percentage of 
IFNγ-producing CD4+ T cells was seen in the lungs after i.t. immunization with cis kMA as 
compared to liposome-formulated OVA as such (Fig. 5A). In contrast to a weak local Th1 
response, immunization with cis mMA and cis kMA resulted in a strong increase in IL-17-
producing CD4+ T cells in the lung (Fig. 5B). 
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Figure 4 | Antigen-specific B cell response after subcutaneous mycolic acid immunization. Mice 
were immunized s.c. at days 0 and 21 either with PBS, OVA alone or with OVA in emulsion with 
AddaVax or formulated in liposomes with or without mycolic acids. (A-B) The titer of OVA-specific 
IgG1 and IgG2c was measured in the serum at day 28 by ELISA. (C) The number of activated B cells 
(live CD19+ Gl7high IgM- IgD-) was measured in the inguinal lymph nodes by flow cytometry. These 
results show one representative experiment out of two independent experiments. Data are mean ±SD, 
n = 5 mice per group. Statistical analysis between two groups was performed using a Mann-Whitney 
test. Significant p-values were ranked as p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***). 
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Figure 5 | Number of IFNγ- and IL-17-producing CD4+ T cells in lungs after pulmonary mycolic 
acid immunization. Mice were immunized i.t. at days 0 and 21 either with PBS or OVA alone or with 
OVA formulated in liposomes with or without mycolic acids. (A-B) At day 28, lung cells were 
stimulated with anti-CD3 ex vivo in the presence of GolgiPlug. The number of IFNγ- and IL-17-
producing CD4+ T cells was determined by intracellular cytokine staining and flow cytometry 
analysis. Data are mean ±SD, n = 5 mice per group. Statistical analysis between two groups was 
performed using a Mann-Whitney test. Significant p-values were ranked as p < 0.05 (*), p < 0.01 (**), 
and p < 0.001 (***). 
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1.4 Discussion 
 
Most vaccine adjuvants that are currently used in humans confer humoral immunity and are 
not adequate to protect against pathogens that are controlled by cellular immune responses. 
Heat-killed mycobacteria formulated in CFA and various mycobacterial cell wall components, 
like trehalose dimycolate (TDM), have been shown to be strong Th1-inducing adjuvants but 
are too toxic for use in humans11–14. In this study we addressed the adjuvant potential of the 
mycobacterial cell wall component, mycolic acid, which shows a milder pathological profile 
as compared to TDM and complex mycobacterial preparations such as CFA2.  
Mycolic acids are highly hydrophobic long-chain α-alkyl β-hydroxy fatty acids present in the 
outer membrane of M. tuberculosis, differing in their molecular structure depending on the 
nature and the stereochemistry of the functional groups in the meromycolate chain5. The 
chemical synthesis of mycolic acids with a defined molecular structure identical to naturally 
occurring mycolic acids15–21 has enabled the discovery of mycolic acid features related to their 
structural complexity. For instance, analysis of mycolic acid-elicited lung inflammation 
revealed a strong dependence of the innate inflammatory response on mycolic acid 
stereochemistry and functional groups4. The differential effect of mycolic acid structure on 
innate immune activation in the lung, led us to compare the relationship between the 
molecular structure of the mycolic acids and their ability to drive adaptive immunity in 
mycolic acid-immunized mice. While mycolic acids have previously already been described 
as important lipid antigens in the development of cellular and humoral anti-mycobacterial 
immune responses22,23, this is first study to explore their role as immunomodulator of these 
adaptive immune responses. 
We addressed the contribution of synthetic mycolic acids, differing in oxygenation class and 
cis versus trans proximal cyclopropane configuration, to the development of T cell-mediated 
immunity after prime-boost subcutaneous immunization. The different mycolic acid 
formulations were compared to AddaVax, a squalene based emulsion resembling the adjuvant 
MF59 which is used in influenza vaccines in Europe1. We showed that subcutaneous delivery 
of individual liposome-formulated mycolic acids elicited distinct antigen-specific CD4+ Th1 
and cytotoxic CD8+ T cell immune responses dependent on the molecular structure (Table 1). 
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CD8+ IFNγ 
spleen 
CD4+ IFNγ 
spleen 
IgG1 
serum 
IgG2c 
serum 
cis αMA ++ + + - 
cis mMA + + - - 
trans mMA + + - - 
cis kMA ++ ++ + - 
trans kMA epi - - - - 
 
Table 1 | Overview of the antigen-specific T cell and B cell immune response after prime-boost 
subcutaneous mycolic acid immunization. The elicited immune response after mycolic acid 
immunization was compared to AddaVax immunization and is rated as (++) if a strong immune 
response was induced, either comparable to or better than AddaVax; as (+) if an increased response 
was seen but lower than AddaVax; and as (–) if no response was seen. 
 
Subcutaneous immunization with cis αMA resulted in a robust induction of IFNγ-producing T 
cells in the spleen already one week after the first immunization, whereas no response was 
seen for AddaVax immunization at that time. However, following boost immunization with 
cis αMA only a modest increase for the CD8+ IFNy response and no increase for the CD4+ 
IFNγ response was observed. In addition, the rapid immune response seen for this particular 
mycolic acid after primary immunization is highly interesting as in a previous report cis αMA 
did not induce a local innate inflammatory response in the lungs4. In addition, a toxicity study 
performed in rabbits showed no signs of inflammation after subcutaneous cis αMA 
immunization (personal communication with Prof. J. Verschoor). This indicates that adjuvant 
potential of a compound is not per se related to immunogenicity and makes cis αMA a 
promising compound for vaccine development. 
The most prominent Th1 and cytotoxic T cell response was observed after subcutaneous 
immunization with cis kMA and was comparable to that seen in mice immunized with 
AddaVax. However, a high number of IFNγ-producing cells in the spleens of these mice were 
also observed in the absence of OVA peptide restimulation. This could be due to the presence 
of other IFNγ-producing cells in the splenocyte cultures such as macrophages and NKT cells. 
This will be verified in future experiments by performing an ELISPOT analysis on CD4 and 
CD8 enriched splenocytes. Another explanation could be that the IFNγ originates from CD4+ 
and CD8+ T cells which are still in a highly activated state one week after boost 
immunization. The latter could be confirmed by preforming another vaccination experiment 
where the read-out of the IFNγ response is performed at a later time point after boost 
immunization. 
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In addition to cellular immunity, we also measured the humoral immune response elicited by 
mycolic acid immunization. After prime-boost subcutaneous immunization with the variant 
mycolic acid formulations we did not detect an increase in OVA-specific IgG1 or IgG2c 
antibodies in the serum as compared to liposomal formulation of OVA alone, whereas 
AddaVax induced a strong anti-OVA antibody response. Nevertheless, mycolic acid 
immunization was associated with a high number of activated B cells in the inguinal lymph 
nodes, especially for cis αMA and cis kMA immunization, indicating the presence of a B cell-
mediated immune response. A possible explanation might be that mycolic acid vaccination is 
inducing the production of anti-mycolic acid antibodies rather than anti-OVA antibodies. This 
could be confirmed by performing a mycolic acid-specific antibody ELISA as well as 
measuring the OVA-specific activated B cells in the lymph node by including fluorescent 
OVA in the staining mixture for flow cytometry analysis. Considering that the presence of 
anti-mycolic acid antibodies could reduce the effectiveness of the booster immunization, 
further investigative studies need to be done.  
Even though subcutaneous immunization does not reflect the natural route of M. tuberculosis 
infection, these experiments did identify the variant individual mycolic acids as important 
modulators of T cell-mediated immunity, with a differential induction of a Th1 and cytotoxic 
T cell immune response depending on the mycolic acid structure. While immunization with 
trans kMA epi did not induce a T cell response, a modest response was seen in mice 
immunized with cis and trans mMA and the most prominent Th1 and cytotoxic T cell 
response was elicited by immunization with cis αMA and cis kMA. The dependence of the 
outcome of the T cell immune response on the structural complexity of the mycolic acids 
illustrates that M. tuberculosis can determine the elicited host immune response by modifying 
its mycolic acids composition. Production of IFNγ by CD4+ Th1 cells and CD8+ cytotoxic T 
cells results in activation of infected macrophages, thus represents an important component in 
the protective immune response to M. tuberculosis24–27. The induction of a T cell response 
upon immunization with mycolic acids could be attributed to both the presence and the nature 
of the functional groups in the meromycolate chain. This is evidenced by the observation that 
immunization with a non-functionalized mycolic acid did not result in a T cell immune 
response. The presence of functional groups in the meromycolate chain is a characteristic of 
pathogenic mycobacteria and is not seen in mycolic acids of non-pathogenic 
Corynebacterineae.  
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In a second approach, we showed that pulmonary delivery of cis mMA and cis kMA, both 
oxygenated mycolic acids with a proximal cis cyclopropane, elicited a strong Th17 response 
in the lungs. The immunomodulatory potential of these two compounds is in accordance with 
a previous report, where we showed that these oxygenated mycolic acids with cis-
cyclopropane stereochemistry elicited the strongest innate inflammatory response after 
administration in the lungs4. Even though the role of Th17 cells in primary M. tuberculosis 
infection remains incompletely understood, their presence in the infected lung is well 
documented28,29.  
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1.5 Material and Methods 
 
Mice 
 
C57BL/6 female mice were purchased from Janvier and were housed under specific 
pathogen-free conditions in individually ventilated cages in a controlled day-night cycle and 
given food and water ad libitum. Mice were 8 weeks at the start of the experiments. All 
experiments were approved by the animal ethics committee of Ghent University, in 
accordance with European guidelines. 
 
Vaccine preparation 
 
Chemically defined mycolic acid isomers were synthesized as described previously15–21. The 
mycolic acids were incorporated into phosphatidyl choline liposomes as described 
previously2–4. Briefly, per mouse 25 µg of mycolic acid was mixed with 4,5 µl phosphatidyl 
choline from egg yolk (Sigma Aldrich) dissolved at 100 mg/ml in choloroform. The 
chloroform was evaporated and 10 µg of OVA grade VII (Sigma) dissolved in 70-100 µl of 
endotoxin free PBS (Lonza) was added to the lipids. To obtain liposomes the suspension was 
vortexed for 10 sec and put in a sonicator bath filled with warm (60-70°C) water for 10 min. 
This was repeated at least 4 times. AddaVax (Invivogen) was used according to the 
manufacterer’s instructions and mixed in a 1:1 ratio with 10 µg OVA grade VII per mouse in 
endotoxin free PBS. 
 
Immunization  
 
Mice were immunized according to a prime-boost vaccination strategy consisting of 2 
immunizations with a 3 week interval. For subcutaneous (s.c.) immunization the mice were 
injected with 100 µl of vaccine formulation at the tail base. For intracheal (i.t.) immunization 
the mice were sedated with ketamine/xylazine and instilled with 70 µl vaccine formulation. 
 
Detection of IFNγ-producing cells by ELISPOT assay  
 
Spleens were pooled per group and passed through a 70µm cell strainer to obtain a single cell 
suspension. Red blood cells were lysed using ACK lysing buffer (BioWhittaker) and 2 x 105 
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cells were cultured on a PVDF plate coated with mIFNγ capture antibody (mIFNγ ELISPOT 
kit, Diaclone) in the presence of 10 µg/ml MHCI-restricted OVA(257-264) peptide or 15 
µg/ml MHCII-restricted OVA(323-339) peptide (both from AnaSpec). For each group, cells 
were plated in quadruplicate. After 24 hours the plate was developed according to the 
manufacturer’s instructions.   
 
Detection of IFNγ protein levels by luminex analysis 
 
Spleens were pooled per group and passed through a 70µm cell strainer to obtain a single cell 
suspension. Red blood cells were lysed using ACK lysing buffer (BioWhittaker) and 2 x 106 
cells were cultured in a round bottom 96 well plate in the presence of 10 µg/ml MHCI-
restricted OVA(257-264) peptide or 15µg/ml MHCII-restricted OVA(323-339) peptide (both 
from AnaSpec). For each group, cells were plated in quadruplicate. After 48 hours the 
supernatans was harvested and the mIFNγ protein level was measured using luminex beads 
(Bio-Rad) according to the manufacturer’s instructions. 
 
Measurement of OVA-specific serum IgG1 and IgG2c levels 
 
OVA-specific IgG1 and IgG2c levels in the serum were determined by ELISA. Briefly, plates 
were coated with OVA (grade V, Sigma Aldrich) and incubated with a 4-fold serial dilution 
of the serum samples. The OVA-bound IgG1 and IgG2c antibodies were detected with a 
HRP-conjugated rat anti-mouse IgG1 or IgG2c detection antibody (Southern Biotec). The 
plate was developed with TMB substrate (BD OptEIA™) and measurements were made at 
450/655nm using a microplate reader after stopping the reaction with sulphuric acid. The 
dilution factor of the serum at a specific absorbance value was calculated and is a measure of 
the amount of OVA-specific IgG1 or IgG2c antibodies present in the serum. 
 
Flow cytometry-based cell counting of activated B cells  
 
Inguinal ymph nodes were first digested for 20 min at 37°C with 1 mg/ml collagenase type IV 
(Sigma Aldrich) and then passed through a 70 µm cell strainer to obtain a single cell 
suspension. To allow for differential cell counting the cells were labelled for the surface 
markers CD19 (1D3), T- and B-Cell Activation Antigen (GL7), IgM (R6-60.2) and IgD (11-
26c.2a) (all from BD Biosciences) together with MHCII (M5/114.15.2) and a live/dead 
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marker (both from eBiosciences). Cells were labelled with the antibodies at 4°C in the 
presence of anti-CD16/32 (2.4G2) (Fc block, BD Biosciences) to block non-specific binding. 
Measurements were performed on a LSRII flow cytometer (BD Biosciences) and analysis was 
done either with FACS Diva software (BD Biosciences) or FlowJo software. Gating strategy 
in supplementary data (Fig. S1). 
 
Intracellular cytokine staining of lung cells 
Lungs are cut into small pieces, digested for 20 min at 37°C with 1 mg/ml collagenase type 
IV (Sigma Aldrich) and 150 U/ml DNaseI (Roche) and passed through a 70 µm cell strainer 
to obtain a single cell suspension. Red blood cells were lysed with ACK lysis buffer and 2 
x106 cells were cultured in a 24 well plate coated with 1 µg anti-CD3 per well to re-stimulate 
the cells. After 1 hour 1 µl/ml brefeldinA (Golgi Plug BD biosciences) was added and 6 hours 
later cells were harvested. To allow for differential cell counting cells were first labelled for 
the surface markers CD45 (30-F11) and CD4 (RM4-5) (both from BD biosciences) together 
with CD3 (17A2) and a fixable live/dead marker (both from eBiosciences). Cells were 
labelled with the antibodies at 4°C in the presence of anti-CD16/32 (2.4G2) (Fc block BD 
Biosciences) to block non-specific binding. After staining, the cells were fixed and 
permealised with Cytofix/Cytoperm solution (BD biosciences) according to the 
manufacturer’s instructions after which they were stained for the intracellular cytokines IL-17 
(TC11-18H10) and IFNγ (XMG1.2) or their isotype controle IgG1 κ (R3-34) conjugated to 
the respective fluorophores (all from BD biosciences). Measurements were performed on a 
LSRII flow cytometer (BD Biosciences) and analysis was done with FACS Diva software 
(BD Biosciences).  
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1.7 Supplementary Data 
 
 
 
Figure S1. Gating strategy activated B cells. Singlet cells were gated based on forward and 
side scatter. In the live CD19+ cell population, activated B cells were defined as MHCII+GL7+ 
and IgM-IgD-. 
  
 
  
    
GENERAL DISCUSSION 
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1. Liver X receptors in eosinophilic asthma 
 
Allergic diseases are increasingly prevalent in the developed world and include allergic 
rhinitis, atopic dermatitis and allergic asthma1,2. Allergy is thought to involve a Th2-bias of 
the immune system due to the reduced exposure to pathogens, known as the hygiene 
hypothesis. However, the exact etiology of allergic diseases remains incompletely understood 
and other environmental factors typical for the Western World, including diet and air 
pollution, have also been associated with the development of allergy. For instance, 
hypercholesterolemia, a condition characterised by elevated serum cholesterol, which shows 
the highest prevalence in Europe and North America3 has been shown to display a positive 
association with the development of allergic asthma, as evidenced by epidemiological studies 
in both adults and children4–9. 
Cholesterol homeostasis is regulated by the nuclear receptor LXR through upregulation of 
genes involved in reverse cholesterol transport. Activation of LXR through oxysterols 
mediates efflux of excess cholesterol from peripheral tissues to high density lipoproteins 
followed by biliary excretion. Apart from its role as a cholesterol regulator, LXR also 
mediates anti-inflammatory properties in several chronic inflammatory diseases. Whereas the 
role of LXR in a multitude of inflammatory diseases is well studied, its involvement in 
allergic diseases remains elusive.  
In this dissertation we addressed the role of the cholesterol-sensing nuclear receptor LXR in 
the development of allergic asthma, a chronic inflammatory disease of the airways 
characterized by IgE production, Th2-driven eosinophilic inflammation and airway reactivity.   
An important feature of allergic disorders, including asthma, is the production of allergen-
specific IgE antibodies. The early allergic immune response, which is elicited after exposure 
to the allergen, is characterized by mast cell activation after allergen-mediated cross-linking 
of IgE bound to the Fc epsilon receptor I (FcεRI) on mast cells10,11. In this study, we showed 
that in an IgE-dependent asthma mouse model, loss of LXR activity resulted in a modest 
increase in allergen-specific IgE levels in the serum after multiple allergen challenges. This is 
consistent with previous studies that showed a negative role for LXR in IgE production 
through inhibition of B cell differentiation12. However, the increase in IgE serum levels upon 
loss of LXR activity observed in this study were very modest and did not correlate with more 
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severe allergic disease as we did not observe an increase but rather a decrease in clinical 
asthma features. This implies that even though multiple studies support a negative role for 
LXR in IgE-mediated responses, the differences in IgE levels upon loss of LXR activity do 
not appear to be of biological significance as they do not contribute to a difference in the 
allergic disease. 
Following mast cell activation, the late phase of an allergic asthma response takes place a few 
hours after the initial allergen challenge and is characterised by airway narrowing and mucus 
hypersecretion together with recruitment and activation of Th2 cells and eosinophils10,11. In 
our study, we showed that mice deficient for both LXR isoforms displayed reduced lung 
eosinophilia, reduced airway elastance and reduced numbers of mucus-secreting cells. The 
reduction in airway inflammation was associated with the loss of LXR activity in 
haematopoietic cells, as evidenced by bone marrow transplant studies. To complement our 
studies in LXR deficient mice, we treated WT mice with LXR agonists to increase LXR 
activity. However, we did not see a clear trend in eosinophil numbers upon LXR agonist 
treatment. This is in accordance with prior studies that also did not observe changes in 
eosinophil numbers upon LXR agonist treatment13,14. It remains to be determined whether the 
agonist treatment timing, delivery route and dosage were appropriate. Future experiments will 
address daily oral gavage and formulation of the LXR agonist in the feed of the mice as 
alternative delivery routes. In addition, combining high-cholesterol diet with LXR 
antagonist15 treatment in an asthma mouse model might further strengthen the hypothesis that 
LXR activation, due to hypercholesterolemia, aggravates eosinophilic airway inflammation. 
Eosinophils are recruited to the lungs by cytokines that are released from activated Th2 cells 
and by a range of chemokines, most notably those of the eotaxin family10,11. While the nature 
of the Th2 response was not altered, CD4+ T cells in the lungs of LXR deficient mice were 
reduced in number and expressed lower levels of the Th2 cytokines IL-4, IL-5 and IL-13. In 
accordance to a reduced expression by CD4+ T cells, we also observed significantly decreased 
protein levels of the cytokine IL-5 and IL-13 in the BALF of LXR deficient mice. Together, 
our results show that loss of LXR activity results in reduced eosinophil inflammation due to a 
decrease in type 2 cytokine expression. A positive regulatory role for LXR as a direct 
transcriptional regulator of type 2 cytokine expression is further supported by a recent study 
that identified the mouse IL-5 gene as a direct LXR target gene with a putative LXRE in its 
promoter region16. The IL-5 gene lies in a Th2 cytokine locus also encompassing the IL-4 and 
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IL-13 gene, located on mouse chromosome 11qB1.3 and human chromosome 5q31.1. These 
Th2 cytokine-encoding genes have been shown to be regulated in a coordinate manner17–20. 
Further research will be required to address whether LXR regulates these Th2 cytokine-
encoding genes in a separate manner, with LXREs being present in the individual Th2 
cytokine promoter regions, or in a coordinate manner.  
Aside from eosinophil recruitment to the lungs, increased eosinophil differentiation in the 
bone marrow is another important feature of eosinophilic inflammation21. Eosinophils develop 
downstream of the granulocyte/monocyte progenitor (GMP) in the bone marrow. Upon 
eosinophil lineage commitment, these progenitor cells acquire IL-5Rα on their surface and 
differentiate into mature eosinophils under the influence of IL-5, IL-3 and GM-CSF21. Under 
conditions of eosinophilia, IL-5 represents the major maturation factor for eosinophils and 
defective IL-5 signalling, as seen in IL-5 deficient mice, results in severely reduced tissue and 
blood eosinophilia upon exposure to helminth infection or during allergic asthma22–27. In 
accordance with the decreased IL-5 protein levels seen in the serum of LXR deficient mice 
during allergic asthma, we also observed a decrease in the number of eosinophils in the blood 
and bone marrow. These findings further support an important role for LXR in eosinophilic 
inflammation through promoting IL-5 mediated eosinophil maturation in the bone marrow. 
However, while displaying normal eosinophil levels in steady-state and reduced eosinophil  
numbers during allergic asthma, we also showed that LXR deficient mice showed highly 
increased numbers of lineage-committed eosinophil progenitor cells in the bone marrow, both 
during steady-state and eosinophilic asthma. Aside from an increase in eosinophil progenitor 
cells, LXR deficient mice also showed an increase in their ancestral cells namely the GMP 
and the common myeloid progenitor (CMP). We suspect this results from hyperproliferation 
of these progenitor cells due to an increased sensitivity to IL-3 and GM-CSF signalling, as 
this has already been described in mice displaying intracellular cholesterol accumulation as 
the result of ABCA1 and ABCG1 deficiency28. While these studies showed that the 
progenitor cell hyperproliferation resulted in increased levels of monocytes, neutrophils and 
eosinophils in the blood, we did not observe any changes in the levels of these cells. 
Therefore, we speculate that, apart from hyperproliferation, these progenitor cells display a 
maturation arrest, potentially through a disrupted LXR-PU.1 cross-talk. 
In a broader sense, we speculate that LXR signalling may underlie the positive association 
that has been described between elevated cholesterol levels in the blood and asthma in several 
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epidemiological studies4–9. Moreover, hypercholesterolemia in mice has also been shown to 
result in more severe allergen-induced eosinophilic airway inflammation as well as increased 
AHR and goblet cell hyperplasia29,30. Hypercholesterolemia represents a condition that highly 
activates LXR due to increased availability of endogenous LXR ligands. This implies that 
while LXR activation promotes removal of excess cholesterol through reverse cholesterol 
transport, it might also promote the development of allergic asthma due to increased 
expression of type 2 cytokines.  
It is noteworthy in this context that LXR deficient mice themselves do not show an increase in 
serum cholesterol levels and are accordingly not hypercholesterolemic19. However, loss of 
LXR activity does result in intracellular cholesterol accumulation in peripheral tissue 
macrophages20. In addition to LXR deficient mice, ABCG1-/- mice, which also display 
intracellular cholesterol accumulation due to defective cholesterol efflux, have been shown to 
display a reduction in Th2-mediated airway inflammation33. This implies that intracellular 
cholesterol accumulation might attenuate eosinophilic airway inflammation through a 
mechanism independent of LXR signalling. 
In contrast to our data in allergic asthma, topical administration of LXR agonists has been 
shown to reduce the clinical signs in a hapten-induced mouse model of atopic dermatitis34. 
The therapeutic effect of LXR activation in atopic dermatitis was associated with reduced 
tissue eosinophilia and reduced production of the pro-inflammatory cytokines IL-1α and 
TNFα34. Although chronic inflammation is a well-known feature of atopic dermatitis, it is 
becoming more and more recognised that permeability barrier abnormality is the main driver 
of the disease pathogenesis35. Considering that LXR is an important regulator of epidermal 
differentiation and barrier function36,37 and that epidermal structure and function were 
normalised in the atopic dermatitis mouse model upon LXR agonist treatment34, it is thought 
that LXR-mediated normalization of the epidermal barrier function accounts for the observed 
decrease in inflammation.  
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2. Mycolic acid vaccination 
 
Mycolic acids are highly hydrophobic branched long-chain α-alkyl β-hydroxyl fatty acids 
present in the outer membrane of Corynebacterineae, a group of bacteria including 
Mycobacterium tuberculosis. The mycolic acids present in the cell wall of M. tuberculosis 
display a common general structure but with variable functional groups in the meromycolate 
chain38. Apart from their structural role, mycolic acids are also important mediators of host-
pathogen interactions and this feature is strongly dependent on their structural complexity. For 
instance, mycolic acid-elicited lung inflammation revealed a dependence of the innate 
immune response on mycolic acid stereochemistry and functional groups, ranging from pro- 
to anti-inflammatory39. In addition, mycolic acids have been identified as important lipid 
antigens in T cell and B cell-mediated anti-mycobacterial adaptive immune responses40,41. 
However, the role of mycolic acids as immunomodulators of the anti-mycobacterial adaptive 
immune response has not yet been investigated and was the focus of the second part of this 
dissertation. We investigated the immune response elicited after immunization with single 
synthetic mycolic acids, varying in oxygenation class and cis versus trans proximal 
cyclopropane configuration and representing the mycolic acids naturally occurring in the cell 
wall of M. tuberculosis38.  
We showed that after subcutaneous immunization the mycolic acid compounds elicited a 
distinct CD4+ Th1 and cytotoxic CD8+ T cell immune responses in the spleen dependent on 
the molecular structure. The most prominent T cell immune response was elicited by 
immunization with cis αMA and cis kMA and was comparable to that seen in mice 
immunized with AddaVax. This offers their potential use in the development of vaccines 
combating intracellular pathogens that are controlled by Th1 and cytotoxic T cell responses, 
including those causing tuberculosis, leishmaniasis and malaria, as well as for tumor 
immunotherapy. 
In a second approach, we delivered the mycolic acids through the natural route of M. 
tuberculosis infection and addressed the local immune response after pulmonary vaccination. 
Here, we demonstrated that intracheal delivery of cis mMA and cis kMA resulted in a strong 
Th17 response in the lungs. Mucosal vaccination has gained a lot of interest in the 
development of vaccines combating pathogens that access the body through mucosal 
membranes42–45. In addition, many mucosal vaccination approaches induce robust Th17 
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responses46,47. Here, we showed that intratracheal immunization with cis mMA and cis kMA 
elicited a strong Th17 response in the lungs. Considering the mild inflammatory profile 
elicited by the single mycolic acids in the lung39, pulmonary vaccination with select mycolic 
acids offers a promising strategy for the induction of local Th17-mediated immune responses 
to combat a variety of lung pathogens. For instance, Th17 cells are involved in immunity to 
extracellular pathogens, such as Bordetella pertussis48 and  Klebsiella pneumoniae49, as well 
as fungal infections, including Candida albicans50. However, the list of intracellular 
pathogens where Th17-mediated immunity is implicated is steadily growing. For instance, 
vaccination-induced memory Th17 cells in the lungs have also been shown to enhance 
protection against M. tuberculosis47,51.  
Overall our data shows that mycolic acids contribute to the development of cellular immunity. 
The strength of the elicited immune response is related to the structural complexity of the 
mycolic acids and can thus be modulated by the bacteria by changing its mycolic acid 
composition. In addition, we demonstrated that the adjuvant activity of the distinct mycolic 
acids was attributable to the presence and the nature of the functional groups in the 
meromycolate chain, a feature that is characteristic of pathogenic mycobacteria. 
The use of select synthetic mycolic acids, conferring either Th1 and cytotoxic T cell-mediated 
immunity after subcutaneous delivery, or Th17-mediated immunity after pulmonary delivery, 
represent a promising new strategy for exploiting the immunostimulatory activity of 
mycobacterial cell wall components in vaccine development without the associated toxicity 
seen for complex mycobacterial preparations such as CFA. The toxicity associated with 
subcutaneous injection of mycolic acids was addressed by a study performed by our 
collaborators at the University of Pretoria. They investigated the severity of inflammation at 
the injection site after subcutaneous immunization of rabbits with the variant liposome-
formulated single synthetic mycolic acids, including cis αMA, cis and trans methoxyMA and 
cis and trans ketoMA epi. These studies showed that immunization with none of the five 
investigated mycolic acids induced any visual signs of inflammation. However, during 
pathological analysis of the skin, mice immunized with cis ketoMA epi did show a moderate, 
multifocal, subepidermal microgranulamatous inflammatory reaction, characterised by the 
presence of eosinophils, plasma cells and macrophages (personal communication with Prof. J. 
Verschoor). Considering that in our study the single epimeric cis ketoMA showed a highly 
promising cellular immune response and this synthetic mycolic acid was not tested in the 
rabbit toxicity study, further investigations towards its toxicity pattern ought to be done.  
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As both Th1- and Th17-inducing adjuvants have been shown to confer protective anti-
mycobacterial immunity, our next objective is to test the various mycolic acid compounds for 
their protective immunity against M. tuberculosis infection in a mouse model (in collaboration 
with Marta Romano and Kris Huygen, Institute of Public Health Brussels). The immunization 
strategy that will be employed is a double prime immunization consisting of both 
subcutaneous and intratracheal immunization followed by two booster subcutaneous 
immunizations. The M. tuberculosis specific antigen that will be used is PPE44, which has 
been shown to function as a protective antigen in tuberculosis vaccination52. The protective 
efficacy of the different mycolic acid formulations will be compared to BCG vaccination.  
A second perspective is to screen the sugar esters of these mycolic acid compounds for their 
adjuvant potential. Depending on the sugar component, several types of mycolate esters exist, 
namely trehalose mono-mycolaat (TMM), trehalose di-mycolaat (TDM), glucose mono-
mycolaat (GMM), glycerol mono-mycolaat (GroMM) and arabinose mono-mycolaat 
(ArMM). The best described mycolate ester is TDM, which has been shown to induce strong 
T cell immune responses53–55 but is too toxic for use in human vaccines56,57. However, the use 
of other mycolate esters displaying milder pathological profiles presents a promising strategy 
for vaccine development. A mycolic acid sugar ester that has already been described to confer 
a protective Th1 immune response is glycerol mono-mycolate58.  
3. Crosstalk between mycolic acids and LXR biology 
 
This dissertation addressed two distinct research topics on the interaction between lipids or 
lipid biology and inflammation. However, a potential crosstalk between mycolic acids and 
LXR-regulated cholesterol homeostasis also needs to be highlighted as mycolic acids and 
cholesterol display highly similar structures59. Moreover, analysis of the crystal structure of 
LXRβ has revealed a remarkable capacity of the ligand binding pocket to accommodate a 
broad range of structurally different ligands60. Apart from oxysterols, LXR has also been 
shown to bind a wide variety of other ligands including poly-unstarurated fatty acids but also 
several plant sterols and stanols which are structurally related to cholesterol61. Even though 
there is no data supporting LXR binding of mycolic acids, it does not seem unlikely. Apart 
from displaying a structural cholesteroid nature, mycolic acids also impact cellular cholesterol 
homeostasis though induction of lipid accumulation in macrophages62. The molecular 
mechanism of this mycolic acid-induced foam cell formation is not known. As discussed in 
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the introduction, foam cells classically develop due to a dysregulation in the balance between 
influx and efflux of lipids in the cell. Seeing as LXRs are cellular cholesterol regulators that 
mediate cholesterol efflux, LXR inactivation results in spontaneous foam cell formation32. As 
such, mycolic acid-induced foam cells display an ‘inactivated’ LXR status as was evidence by 
the absence of upregulation of classical lipid efflux genes including ABCA1 and ABCG1 
(unpublished data) concurrent with the accumulation of cholesterol, suggesting that mycolic 
acid might reduce LXR activity to promote lipid accumulation. A role for LXR inactivation in 
pathogen-induced foam cell formation has already been documented for Chlamydia 
pneumonia infection. Lipid accumulation was shown to result from inhibition of LXR activity 
through TLR3- or TLR4-mediated IRF3 signalling63,64. 
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